JP2015120644A - Radioactively labeled ligand of v1b receptor - Google Patents
Radioactively labeled ligand of v1b receptor Download PDFInfo
- Publication number
- JP2015120644A JP2015120644A JP2013264135A JP2013264135A JP2015120644A JP 2015120644 A JP2015120644 A JP 2015120644A JP 2013264135 A JP2013264135 A JP 2013264135A JP 2013264135 A JP2013264135 A JP 2013264135A JP 2015120644 A JP2015120644 A JP 2015120644A
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound
- receptor
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003446 ligand Substances 0.000 title abstract description 22
- 150000001875 compounds Chemical class 0.000 claims abstract description 144
- 102000004136 Vasopressin Receptors Human genes 0.000 claims abstract description 40
- 108090000643 Vasopressin Receptors Proteins 0.000 claims abstract description 40
- 150000003839 salts Chemical class 0.000 claims abstract description 29
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 25
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 21
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 20
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 16
- 239000002904 solvent Substances 0.000 claims description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- 125000005843 halogen group Chemical group 0.000 claims description 15
- -1 4-nitrobenzenesulfonyloxy group Chemical group 0.000 claims description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 238000002372 labelling Methods 0.000 claims description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 9
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 5
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 5
- 125000005948 methanesulfonyloxy group Chemical group 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 239000000032 diagnostic agent Substances 0.000 claims description 4
- 229940039227 diagnostic agent Drugs 0.000 claims description 4
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 3
- 238000003325 tomography Methods 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 abstract description 4
- 230000002285 radioactive effect Effects 0.000 abstract description 4
- 238000003745 diagnosis Methods 0.000 abstract description 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 54
- 229910052739 hydrogen Inorganic materials 0.000 description 40
- 235000002639 sodium chloride Nutrition 0.000 description 21
- 239000000243 solution Substances 0.000 description 20
- 238000002600 positron emission tomography Methods 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 241000282693 Cercopithecidae Species 0.000 description 17
- 206010062767 Hypophysitis Diseases 0.000 description 17
- 210000003635 pituitary gland Anatomy 0.000 description 17
- 238000003786 synthesis reaction Methods 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 102000005962 receptors Human genes 0.000 description 16
- 108020003175 receptors Proteins 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 15
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 14
- 239000007787 solid Substances 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 238000004949 mass spectrometry Methods 0.000 description 12
- 210000004556 brain Anatomy 0.000 description 11
- 238000000132 electrospray ionisation Methods 0.000 description 11
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 101800001144 Arg-vasopressin Proteins 0.000 description 9
- 102400000059 Arg-vasopressin Human genes 0.000 description 9
- 238000012879 PET imaging Methods 0.000 description 9
- 238000002059 diagnostic imaging Methods 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 7
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 235000019439 ethyl acetate Nutrition 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 102400000739 Corticotropin Human genes 0.000 description 4
- 101800000414 Corticotropin Proteins 0.000 description 4
- 235000011054 acetic acid Nutrition 0.000 description 4
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 239000007810 chemical reaction solvent Substances 0.000 description 4
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 4
- 229960000258 corticotropin Drugs 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000002274 desiccant Substances 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000012046 mixed solvent Substances 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 238000001308 synthesis method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 3
- 210000004198 anterior pituitary gland Anatomy 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- INQOMBQAUSQDDS-BJUDXGSMSA-N iodomethane Chemical compound I[11CH3] INQOMBQAUSQDDS-BJUDXGSMSA-N 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 210000003752 saphenous vein Anatomy 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical class O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 2
- WMPDAIZRQDCGFH-UHFFFAOYSA-N 3-methoxybenzaldehyde Chemical compound COC1=CC=CC(C=O)=C1 WMPDAIZRQDCGFH-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 238000006751 Mitsunobu reaction Methods 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 210000000692 cap cell Anatomy 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- OKTJSMMVPCPJKN-BJUDXGSMSA-N carbon-11 Chemical compound [11C] OKTJSMMVPCPJKN-BJUDXGSMSA-N 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000006266 etherification reaction Methods 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-BJUDXGSMSA-N methanedione Chemical compound O=[11C]=O CURLTUGMZLYLDI-BJUDXGSMSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- FSKYZRCACCHDGR-UHFFFAOYSA-N 1h-pyrido[3,2-d]pyrimidin-4-one Chemical class C1=CN=C2C(=O)N=CNC2=C1 FSKYZRCACCHDGR-UHFFFAOYSA-N 0.000 description 1
- HTZWATKNQYOOIT-UHFFFAOYSA-N 2-(1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane Chemical compound O1CCOB1B1OCCO1 HTZWATKNQYOOIT-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- PQECODMSWJOUAT-UHFFFAOYSA-N 4-(3-chloropropyl)morpholine;hydrochloride Chemical compound [Cl-].ClCCC[NH+]1CCOCC1 PQECODMSWJOUAT-UHFFFAOYSA-N 0.000 description 1
- YDNWTNODZDSPNZ-UHFFFAOYSA-N 6-methoxypyridine-2-carbaldehyde Chemical compound COC1=CC=CC(C=O)=N1 YDNWTNODZDSPNZ-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- CGXSBKCFLKRBQD-UHFFFAOYSA-N BrC1=CC2=C(N=C(N(C2=O)CC(=O)NC(C)(C)C)C2=CC(=CC=C2)OC)N=C1 Chemical compound BrC1=CC2=C(N=C(N(C2=O)CC(=O)NC(C)(C)C)C2=CC(=CC=C2)OC)N=C1 CGXSBKCFLKRBQD-UHFFFAOYSA-N 0.000 description 1
- WMGREKGMQTVHKC-UHFFFAOYSA-N BrC1=CC2=C(N=C(N(C2=O)CC(=O)NC(C)(C)C)C2=NC(=CC=C2)OC)N=C1 Chemical compound BrC1=CC2=C(N=C(N(C2=O)CC(=O)NC(C)(C)C)C2=NC(=CC=C2)OC)N=C1 WMGREKGMQTVHKC-UHFFFAOYSA-N 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108091006068 Gq proteins Proteins 0.000 description 1
- 102000052606 Gq-G11 GTP-Binding Protein alpha Subunits Human genes 0.000 description 1
- 108091006065 Gs proteins Proteins 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 101150003085 Pdcl gene Proteins 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Inorganic materials [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- XVBXOXSGLCFKBN-UHFFFAOYSA-N ethane-1,2-diamine tetrahydrochloride Chemical compound Cl.Cl.Cl.Cl.NCCN XVBXOXSGLCFKBN-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 230000000640 hydroxylating effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005921 isopentoxy group Chemical group 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 125000006606 n-butoxy group Chemical group 0.000 description 1
- 125000003935 n-pentoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- ACYFWRHALJTSCF-UHFFFAOYSA-N n-tert-butylacetamide Chemical compound CC(=O)NC(C)(C)C ACYFWRHALJTSCF-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000005484 neopentoxy group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000001883 posterior pituitary gland Anatomy 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940075993 receptor modulator Drugs 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 125000005920 sec-butoxy group Chemical group 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005922 tert-pentoxy group Chemical group 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- 125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
本発明は、アルギニン−バソプレッシン（ＡＶＰ）の受容体である、バソプレッシンＶ１ｂ受容体に特異的に結合する放射性同位元素標識リガンドに関する。特に、陽電子断層撮影（positron emission tomography；ＰＥＴ)等の画像診断に使用するための放射性同位元素標識リガンドに関する。 The present invention relates to a radioisotope-labeled ligand that specifically binds to the vasopressin V1b receptor, which is a receptor for arginine-vasopressin (AVP). In particular, the present invention relates to a radioisotope-labeled ligand for use in diagnostic imaging such as positron emission tomography (PET).
ＡＶＰは９個のアミノ酸よりなるペプチドである。ＡＶＰは、脳内の神経細胞で生合成され、下垂体後葉から血液中へと分泌され、血圧及び体液量の調節を行う。また、ＡＶＰは下垂体前葉へと分泌され、副腎皮質刺激ホルモン（ＡＣＴＨ）の分泌を刺激する。 AVP is a peptide consisting of 9 amino acids. AVP is biosynthesized by nerve cells in the brain, secreted from the posterior pituitary gland into the blood, and regulates blood pressure and fluid volume. AVP is also secreted into the anterior pituitary gland and stimulates the secretion of adrenocorticotropic hormone (ACTH).
ＡＶＰ受容体は、これまでＶ１ａ、Ｖ１ｂ及びＶ２受容体の３つのサブタイプがクローニングされており、いずれもＧタンパク質共役型受容体である。Ｖ１ａ及びＶ１ｂ受容体はＧｑタンパク質と共役し、受容体の活性化は、イノシトールリン脂質の代謝を亢進させまた、細胞内Ｃａ2+濃度を上昇させる（非特許文献１及び非特許文献２参照）。また、Ｖ２受容体は、Ｇｓタンパク質と共役し、受容体の活性化は、細胞内サイクリックＡＭＰ量を増加させる。Ｖ１ａ受容体は、脳、肝臓、副腎、血管平滑筋などに発現している。Ｖ２受容体は腎臓などに発現している。Ｖ１ｂ受容体は、脳、下垂体などに発現し、脳内では、視床下部、嗅球、海馬、大脳皮質、線条体、小脳などに発現している（非特許文献３及び非特許文献４参照）。Ｖ１ｂ受容体ノックアウトマウスでは、ＡＶＰ誘発によるＡＣＴＨ分泌が減少している（非特許文献５参照）。そのため、Ｖ１ｂ受容体はＡＶＰによる下垂体前葉からのＡＣＴＨ分泌に関わることが示唆される。 The AVP receptor has so far been cloned into three subtypes of V1a, V1b and V2 receptors, all of which are G protein-coupled receptors. V1a and V1b receptors are coupled to Gq protein, and activation of the receptor enhances inositol phospholipid metabolism and increases intracellular Ca 2+ concentration (see Non-Patent Documents 1 and 2). . In addition, the V2 receptor is coupled to the Gs protein, and activation of the receptor increases the amount of intracellular cyclic AMP. V1a receptor is expressed in brain, liver, adrenal gland, vascular smooth muscle and the like. V2 receptor is expressed in the kidney and the like. V1b receptors are expressed in the brain, pituitary gland, etc., and are expressed in the hypothalamus, olfactory bulb, hippocampus, cerebral cortex, striatum, cerebellum, etc. in the brain (see Non-Patent Document 3 and Non-Patent Document 4). ). In V1b receptor knockout mice, AVP-induced ACTH secretion is reduced (see Non-Patent Document 5). Therefore, it is suggested that the V1b receptor is involved in ACTH secretion from the anterior pituitary gland by AVP.
近年、非侵襲的イメージング技術の医療や創薬への利用が進んでいる。臨床では、がんなどの病気の診断、心臓や脳での活動の測定、および開発候補品の標的タンパク質への結合割合の評価に使用されている。また、前臨床では、病態モデル動物の解析や放射性同位元素標識体リガンドの実験動物での体内動態のトレースに使用されている。特に、ＰＥＴは非侵襲的イメージング技術の中で、微量なシグナルを高感度で検出することに優れ、定量性もあるため広範に利用されるようになっている。この技術を使用するためには、陽電子放出核種で標識したリガンドが必要であり、このリガンドは生体内に投与した後も安定して目的臓器に到達し、体内から速やかに排泄される性質を有することが好ましい。 In recent years, the use of non-invasive imaging techniques for medicine and drug discovery has progressed. In clinical practice, it is used to diagnose diseases such as cancer, measure activity in the heart and brain, and evaluate the rate of binding of development candidates to target proteins. In preclinical practice, it is used to analyze pathological model animals and trace the pharmacokinetics of radioisotope-labeled ligands in experimental animals. In particular, PET is widely used in non-invasive imaging techniques because it is excellent in detecting a very small amount of signal with high sensitivity and has quantitative properties. In order to use this technology, a ligand labeled with a positron emitting nuclide is required, and this ligand has the property of reaching the target organ stably after being administered in vivo and being rapidly excreted from the body. It is preferable.
バソプレッシンＶ１ｂ受容体に特異的に結合する放射性同位元素標識リガンドは、ＰＥＴ等の画像診断技術を用いて非侵襲的にバソプレッシンＶ１ｂ受容体の発現量、または受容体の分布の変化を測定するために有用である。また、非標識体のバソプレッシンＶ１ｂ受容体リガンドを投与した後に、微量の放射性同位元素標識リガンドを投与しＰＥＴで評価することで、バソプレッシンＶ１ｂ受容体への非標識体バソプレッシンＶ１ｂ受容体リガンドの結合を間接的に定量することが可能となり、ヒトでの投与量を設定するのに有用である。これまでにバソプレッシンＶ１ｂ受容体への放射性同位元素標識リガンドに関する報告がなされているが、非標識体バソプレッシンＶ１ｂ受容体リガンドによる放射能取り込み抑制は確認されていない（非特許文献６参照）。従って、ヒトでの画像診断を行うために有用な、バソプレッシンＶ１ｂ受容体に特異的に結合する放射性同位元素標識リガンドの創製が求められている。 A radioisotope-labeled ligand that specifically binds to the vasopressin V1b receptor is used to non-invasively measure changes in the expression level of the vasopressin V1b receptor or receptor distribution using imaging techniques such as PET. Useful. In addition, after administration of unlabeled vasopressin V1b receptor ligand, administration of a trace amount of radioisotope-labeled ligand and evaluation by PET enables binding of unlabeled vasopressin V1b receptor ligand to vasopressin V1b receptor. Indirect quantification is possible, which is useful for setting a human dose. So far, there have been reports on radioisotope-labeled ligands to vasopressin V1b receptor, but no inhibition of radioactivity uptake by unlabeled vasopressin V1b receptor ligand has been confirmed (see Non-Patent Document 6). Accordingly, there is a demand for the creation of a radioisotope-labeled ligand that specifically binds to the vasopressin V1b receptor, which is useful for diagnostic imaging in humans.
また、Ｖ１ｂ受容体に特異的に結合するピリドピリミジン−４−オン誘導体は、特許文献１〜３に開示されているが、放射性同位元素標識体及びそれらの製造方法の開示はない。 Moreover, although the pyridopyrimidin-4-one derivative couple | bonded specifically with a V1b receptor is disclosed by patent documents 1-3, there is no disclosure of a radioisotope label and their manufacturing method.
本発明の目的は、バソプレッシンＶ１ｂ受容体に特異的に結合する新規な放射性同位元素標識リガンドを提供することにある。さらには、生体内に投与した後に代謝を受けずに安定であり、目的臓器（例えば、脳など）に十分な量が特異的に集積し、かつ生体内から速やかに排泄されるという画像診断用に好ましい特性を有した放射性同位元素標識リガンドを提供することにある。 It is an object of the present invention to provide a novel radioisotope-labeled ligand that specifically binds to the vasopressin V1b receptor. Furthermore, it is stable without being metabolized after being administered in vivo, and a sufficient amount specifically accumulates in the target organ (eg, brain) and is rapidly excreted from within the body. It is another object of the present invention to provide a radioisotope-labeled ligand having favorable characteristics.
本発明者らは前述した課題を解決する目的で鋭意探索研究した結果、優れた放射性同位元素標識リガンド（以下、「本発明の化合物」とも記載する）、及びその製造方法（以下、「本発明の製造方法」とも記載する）を見出し、本発明を完成した。 As a result of diligent search for the purpose of solving the above-mentioned problems, the present inventors have found that an excellent radioisotope-labeled ligand (hereinafter also referred to as “compound of the present invention”) and a method for producing the same (hereinafter referred to as “the present invention”). And the present invention was completed.
すなわち、本発明は、以下のものに関するが、これらに限定されない。
（１）下記一般式（Ｉ）に示される化合物又はその製薬学的に許容される塩
That is, the present invention relates to the following, but is not limited thereto.
(1) A compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof
［上記一般式（Ｉ）において、
Ｘは、ＣＨ又はＮを示し、
Ｒ1は、Ｃ1-5アルキル（該Ｃ1-5アルキルはヒドロキシ、ハロゲン原子、シアノ、Ｃ3-7シクロアルキル、及びＣ1-5アルコキシからなる群より選ばれる同一又は異なった１〜３個の置換基で置換されても良い）であり、
Ｒ2は、同一又は異なった１〜３個のハロゲン原子で置換されても良いＣ1-5アルキル基であり、
ここで、Ｒ2は、11Ｃ、18Ｆ、123Ｉ、125Ｉ、131Ｉ、75Ｂｒ、76Ｂｒ及び82Ｂｒからなる群より選ばれる１つの放射性同位元素で標識されている］、
（２）Ｒ2が11Ｃで標識されたメチル基である、（１）に記載の化合物又はその製薬学的に許容される塩、
（３）（１）又は（２）に記載の化合物又はその製薬学的に許容される塩を含有する、バソプレッシンＶ１ｂ受容体標識剤、
（４）（１）又は（２）に記載の化合物又はその製薬学的に許容される塩を含有する、陽電子断層撮影用のバソプレッシンＶ１ｂ受容体標識剤、
（５）（１）又は（２）に記載の化合物又はその製薬学的に許容される塩を含有する、バソプレッシンＶ１ｂ受容体に関連した疾患の診断薬、
（６）（１）又は（２）に記載の化合物又はその製薬学的に許容される塩を含有する、医薬組成物、
（７）（１）又は（２）に記載の化合物又はその製薬学的に許容される塩の製造方法であって、式（ＩＩ）：
[In the above general formula (I),
X represents CH or N;
R 1 is C 1-5 alkyl (the C 1-5 alkyl is the same or different 1-3 selected from the group consisting of hydroxy, halogen atom, cyano, C 3-7 cycloalkyl, and C 1-5 alkoxy. May be substituted with one substituent),
R 2 is a C 1-5 alkyl group which may be substituted with 1 to 3 halogen atoms which are the same or different,
Here, R 2 is labeled with one radioisotope selected from the group consisting of 11 C, 18 F, 123 I, 125 I, 131 I, 75 Br, 76 Br and 82 Br]
(2) The compound according to (1) or a pharmaceutically acceptable salt thereof, wherein R 2 is a methyl group labeled with 11 C.
(3) A vasopressin V1b receptor labeling agent containing the compound according to (1) or (2) or a pharmaceutically acceptable salt thereof,
(4) A vasopressin V1b receptor labeling agent for positron tomography, comprising the compound according to (1) or (2) or a pharmaceutically acceptable salt thereof,
(5) A diagnostic agent for a disease associated with the vasopressin V1b receptor, comprising the compound according to (1) or (2) or a pharmaceutically acceptable salt thereof,
(6) A pharmaceutical composition comprising the compound according to (1) or (2) or a pharmaceutically acceptable salt thereof,
(7) A method for producing the compound according to (1) or (2) or a pharmaceutically acceptable salt thereof, comprising the formula (II):
（式中、Ｒ1、Ｘは上記で定義した通りである）で表される化合物と、式Ｒ2−Ｌ1（Ｒ2は上記で定義した通りであり、Ｌ1は脱離基である）で表される化合物とを、塩基及び溶媒の存在下で反応させることを含む方法、
（８）Ｌ1が、４−ニトロベンゼンスルホニルオキシ基、ｐ−トルエンスルホニルオキシ基、メタンスルホニルオキシ基、及びハロゲン原子からなる群から選ばれる、（７）に記載の方法、
（９）塩基が、炭酸カリウム、炭酸セシウム、水酸化ナトリウム、トリエチルアミン又はジイソプロピルエチルアミンを含む、（７）又は（８）に記載の方法、又は
（１０）溶媒が、テトラヒドロフラン、アセトニトリル、Ｎ，Ｎ−ジメチルホルムアミド、ジメチルスルホキシド、水又はそれらの混合物である、（７）〜（９）のいずれか１項に記載の方法。
Wherein R 1 and X are as defined above, and the formula R 2 -L 1 where R 2 is as defined above and L 1 is a leaving group. And a compound represented by formula (I) in the presence of a base and a solvent,
(8) The method according to (7), wherein L 1 is selected from the group consisting of a 4-nitrobenzenesulfonyloxy group, a p-toluenesulfonyloxy group, a methanesulfonyloxy group, and a halogen atom.
(9) The method according to (7) or (8), wherein the base comprises potassium carbonate, cesium carbonate, sodium hydroxide, triethylamine or diisopropylethylamine, or (10) the solvent is tetrahydrofuran, acetonitrile, N, N- 10. The method according to any one of (7) to (9), which is dimethylformamide, dimethyl sulfoxide, water or a mixture thereof.
本発明の化合物は、目的臓器である下垂体への十分な量の移行が認められた。従って、当該化合物は、生体内に投与した後に代謝を受けずに安定であると考えられる。また、ＰＥＴを用いた画像診断の結果、本発明の化合物は、下垂体におけるバソプレッシンＶ１ｂ受容体が多く発現している部位である下垂体前葉へ特異的に集積することが明らかになった。従って、本発明の化合物は、バソプレッシンＶ１ｂ受容体に特異的に結合すると考えられる。さらに、本発明の化合物は、投与後生体内から速やかに排泄された。このように、本発明の化合物は、ＰＥＴ等の画像診断に好ましい特性を有する。 A sufficient amount of the compound of the present invention was observed to be transferred to the pituitary gland as the target organ. Therefore, the compound is considered to be stable without being metabolized after being administered in vivo. Further, as a result of diagnostic imaging using PET, it was revealed that the compound of the present invention specifically accumulates in the anterior pituitary gland, which is a site where a large amount of vasopressin V1b receptor is expressed in the pituitary gland. Accordingly, the compounds of the present invention are believed to specifically bind to the vasopressin V1b receptor. Furthermore, the compound of the present invention was rapidly excreted from the living body after administration. Thus, the compound of the present invention has preferable characteristics for diagnostic imaging such as PET.
また、非標識体バソプレッシンＶ１ｂ受容体リガンドを投与した後に、本発明の化合物を投与すると、本発明の化合物の取り込み抑制が生じる。従って、本発明の化合物を用いると、当該受容体への非標識体の結合を間接的に定量することが可能となる。 In addition, when the compound of the present invention is administered after administration of the unlabeled vasopressin V1b receptor ligand, uptake of the compound of the present invention is suppressed. Therefore, when the compound of the present invention is used, the binding of the unlabeled substance to the receptor can be indirectly quantified.
すなわち、本発明の化合物は非侵襲的な可視化を可能とし、微量なシグナルを高感度で検出することに優れ、定量性もあるといった好ましい特性を有する。 That is, the compound of the present invention has favorable characteristics such as enabling noninvasive visualization, being excellent in detecting a very small amount of signal with high sensitivity, and being quantitative.
さらに、本発明の製造方法は、放射性同位元素標識リガンドである本発明の化合物の効率的な供給を可能とする。先ず、放射標識化合物を用いる工程は、放射性物質を扱うための特殊な施設で行わなければならない。この点、本発明の製造方法では、そのような工程を最終段階で行うため、特殊な施設での作業量を最小限に抑えることができ、結果として作業の煩雑性を緩和すると共に作業に伴うコストを抑えることができる。また、当該工程を最終段階で行うことは、その後の追加工程があれば生ずるであろう標識化合物のロスを防止することにつながる。さらに、本発明の製造方法は、迅速に行うことができる。この特徴は、半減期の短い同位体を用いて放射標識化合物を製造する際に有利である。 Furthermore, the production method of the present invention enables efficient supply of the compound of the present invention which is a radioisotope labeled ligand. First, the process using a radiolabeled compound must be performed in a special facility for handling radioactive substances. In this respect, in the manufacturing method of the present invention, since such a process is performed in the final stage, the amount of work in a special facility can be minimized, and as a result, the complexity of the work is reduced and the work is accompanied. Cost can be reduced. Moreover, performing the said process in the last stage leads to preventing the loss of the labeling compound which will arise if there exists a subsequent additional process. Furthermore, the production method of the present invention can be performed quickly. This feature is advantageous when producing radiolabeled compounds using isotopes with a short half-life.
本発明において、「Ｃ1-5アルキル基」とは、炭素数１〜５個の直鎖状又は分岐鎖状のアルキル基を意味し、例えばメチル基、エチル基、ｎ−プロピル基、イソプロピル基、ｎ−ブチル基、イソブチル基、ｓｅｃ−ブチル基、ｔｅｒｔ−ブチル基、ｎ−ペンチル基、イソペンチル基、ｔｅｒｔ−ペンチル基又はネオペンチル基等を挙げることができる。 In the present invention, the “C 1-5 alkyl group” means a linear or branched alkyl group having 1 to 5 carbon atoms, such as a methyl group, an ethyl group, an n-propyl group, an isopropyl group. N-butyl group, isobutyl group, sec-butyl group, tert-butyl group, n-pentyl group, isopentyl group, tert-pentyl group or neopentyl group.
本発明において、「Ｃ3-7シクロアルキル基」としては、シクロプロピル基、シクロブチル基、シクロペンチル基、シクロヘキシル基、シクロヘプチル基等を挙げることができる。 In the present invention, examples of the “C 3-7 cycloalkyl group” include a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, and a cycloheptyl group.
本発明において、「Ｃ1-5アルコキシ基」とは、直鎖状又は分岐鎖状の炭素数１〜５個のアルコキシ基を意味し、例えばメトキシ基、エトキシ基、ｎ−プロポキシ基、イソプロポキシ基、ｎ−ブトキシ基、イソブトキシ基、ｓｅｃ−ブトキシ基、ｔｅｒｔ−ブトキシ基、ｎ−ペンチルオキシ基、イソペンチルオキシ基、ネオペンチルオキシ基、ｔｅｒｔ−ペンチルオキシ基等を挙げることができる。 In the present invention, the “C 1-5 alkoxy group” means a linear or branched alkoxy group having 1 to 5 carbon atoms, such as a methoxy group, an ethoxy group, an n-propoxy group, an isopropoxy group. Group, n-butoxy group, isobutoxy group, sec-butoxy group, tert-butoxy group, n-pentyloxy group, isopentyloxy group, neopentyloxy group, tert-pentyloxy group and the like.
本発明において、「ハロゲン原子」とは、フッ素原子、塩素原子、臭素原子又はヨウ素原子である。 In the present invention, the “halogen atom” is a fluorine atom, a chlorine atom, a bromine atom or an iodine atom.
本発明において、「脱離基」としては、アリールスルホニルオキシ基（該アリールスルホニルオキシ基のアリールは、Ｃ1-5アルキル基、ニトロ基又はハロゲン原子等で置換されても良い）、Ｃ1-5アルキルスルホニルオキシ基（該Ｃ1-5アルキルスルホニルオキシ基のＣ1-5アルキル基は、ハロゲン原子で置換されても良い）、ハロゲン原子等を挙げることができる。当該アリールは、単環から２環式の芳香族炭素環であり、フェニル、１−ナフチル、２−ナフチル等の基を挙げることができる。 In the present invention, the “leaving group” is an arylsulfonyloxy group (the aryl of the arylsulfonyloxy group may be substituted with a C 1-5 alkyl group, a nitro group, a halogen atom, or the like), C 1- Examples thereof include a 5- alkylsulfonyloxy group (the C 1-5 alkyl group of the C 1-5 alkylsulfonyloxy group may be substituted with a halogen atom), a halogen atom, and the like. The aryl is a monocyclic to bicyclic aromatic carbocycle, and examples thereof include phenyl, 1-naphthyl, and 2-naphthyl.
当該アリールスルホニルオキシ基（該アリールスルホニルオキシ基のアリールは、Ｃ1-5アルキル基、ニトロ基又はハロゲン原子等で置換されても良い）としては、４−ニトロベンゼンスルホニルオキシ基、ｐ−トルエンスルホニルオキシ基等を挙げることができる。 Examples of the arylsulfonyloxy group (the aryl of the arylsulfonyloxy group may be substituted with a C 1-5 alkyl group, a nitro group, a halogen atom or the like) include a 4-nitrobenzenesulfonyloxy group, p-toluenesulfonyloxy Groups and the like.
当該Ｃ1-5アルキルスルホニルオキシ基（該Ｃ1-5アルキルスルホニルオキシ基のＣ1-5アルキル基は、ハロゲン原子で置換されても良い）としては、メタンスルホニルオキシ基、トリフルオロメタンスルホニルオキシ基等を挙げることができる。 As the C 1-5 alkylsulfonyloxy group (the C 1-5 alkyl group of the C 1-5 alkylsulfonyloxy group may be substituted with a halogen atom), a methanesulfonyloxy group, a trifluoromethanesulfonyloxy group Etc.
本発明において、「塩基」としては、炭酸カリウム、炭酸セシウム、水酸化ナトリウム等の無機塩基や、トリエチルアミン、ジイソプロピルエチルアミン等の有機塩基を挙げることができる。 In the present invention, examples of the “base” include inorganic bases such as potassium carbonate, cesium carbonate and sodium hydroxide, and organic bases such as triethylamine and diisopropylethylamine.
本発明の放射性同位元素標識化合物で使用される好ましい放射性核種は、11Ｃ、18Ｆ、123Ｉ、125Ｉ、131Ｉ、75Ｂｒ、76Ｂｒ又は82Ｂｒである。インビトロでのバソプレッシンＶ１ｂ受容体標識に使用する場合の好ましい核種は125Ｉなどである。画像診断に使用する場合の好ましい核種は、11Ｃ、18Ｆ、123Ｉ、76Ｂｒなどである。画像診断の手法としては、ＰＥＴ、単一光子放射断層撮影（ＳＰＥＣＴ）等が利用可能であるが、感度の点ではＰＥＴが好ましい。 Preferred radionuclides for use in the radioisotope labeled compounds of the present invention are 11 C, 18 F, 123 I, 125 I, 131 I, 75 Br, 76 Br or 82 Br. A preferred nuclide for use in in vitro vasopressin V1b receptor labeling, such as 125 I. Preferred nuclides for use in diagnostic imaging are 11 C, 18 F, 123 I, 76 Br, and the like. PET, single photon emission tomography (SPECT), or the like can be used as an image diagnosis method, but PET is preferable in terms of sensitivity.
本発明における「製薬学的に許容される塩」とは、薬剤的に許容することのできる酸付加塩を意味し、硫酸、塩酸、臭化水素酸、リン酸、硝酸等の無機酸との塩、或いは、酢酸、安息香酸、シュウ酸、乳酸、リンゴ酸、酒石酸、フマル酸、マレイン酸、クエン酸、マロン酸、マンデル酸、グルコン酸、ガラクタル酸、グルコヘプトン酸、グリコール酸、グルタミン酸、メタンスルホン酸、エタンスルホン酸、ベンゼンスルホン酸、ｐ−トルエンスルホン酸、カンファースルホン酸、ナフタレン−２−スルホン酸等の有機酸との塩が含まれる。遊離体から当該塩への変換は従来の方法で行うことができる。 “Pharmaceutically acceptable salt” in the present invention means a pharmaceutically acceptable acid addition salt, and is used with inorganic acids such as sulfuric acid, hydrochloric acid, hydrobromic acid, phosphoric acid and nitric acid. Salt or acetic acid, benzoic acid, oxalic acid, lactic acid, malic acid, tartaric acid, fumaric acid, maleic acid, citric acid, malonic acid, mandelic acid, gluconic acid, galactaric acid, glucoheptonic acid, glycolic acid, glutamic acid, methanesulfone Salts with organic acids such as acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid, naphthalene-2-sulfonic acid are included. Conversion from the educt to the salt can be performed by conventional methods.
なお、本発明の化合物の遊離体が水和物又は溶媒和物を形成する場合、それらも本発明の化合物の範囲内に含まれる。同様に、本発明の化合物の医薬上許容される塩が水和物又は溶媒和物を形成する場合には、それらも本発明の化合物の範囲内に含まれる。また、本発明の化合物は、エナンチオマー、ジアステレオマー、平衡化合物、これらの任意の割合の混合物、ラセミ体等を全て含む。 In addition, when the free body of the compound of this invention forms a hydrate or a solvate, they are also contained in the range of the compound of this invention. Similarly, where pharmaceutically acceptable salts of the compounds of this invention form hydrates or solvates, they are also included within the scope of the compounds of this invention. In addition, the compounds of the present invention include all enantiomers, diastereomers, equilibrium compounds, mixtures of these in any proportion, racemates, and the like.
本発明の化合物において、好ましい態様を以下に挙げる。 Preferred embodiments of the compound of the present invention are listed below.
Ｒ1は、Ｃ1-5アルキルである化合物が好ましく、イソプロピル又はｔｅｒｔ−ブチルである化合物がより好ましく、ｔｅｒｔ−ブチルである化合物がさらに好ましい。 R 1 is preferably a compound which is C 1-5 alkyl, more preferably a compound which is isopropyl or tert-butyl, and even more preferably a compound which is tert-butyl.
Ｒ2は、11Ｃで標識されたメチルであることが好ましい。 R 2 is preferably methyl labeled with 11 C.
好ましくは、Ｒ1はｔｅｒｔ−ブチルであり、Ｒ2は11Ｃで標識されたメチルである。 Preferably R 1 is tert-butyl and R 2 is 11 C-labeled methyl.
本発明の化合物は、バソプレッシンＶ１ｂ受容体を標識化するために、即ち、バソプレッシンＶ１ｂ受容体標識剤として用いることができる。この標識剤は、例えば、ＰＥＴ等を用いる画像診断において有用である。 The compound of the present invention can be used for labeling vasopressin V1b receptor, that is, as a vasopressin V1b receptor labeling agent. This labeling agent is useful in diagnostic imaging using, for example, PET.
本発明の１つの態様は、動物に一般式（Ｉ）に示される化合物又はその製薬学的に許容される塩を有効量投与することを特徴とする、動物におけるバソプレッシンＶ１ｂ受容体の画像診断方法である。 One aspect of the present invention is a method for imaging vasopressin V1b receptor in an animal, comprising administering an effective amount of a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof to the animal. It is.
また、本発明の他の１つの態様は、動物に一般式（Ｉ）に示される化合物又はその製薬学的に許容される塩を有効量投与することを特徴とする、動物の脳におけるバソプレッシンＶ１ｂ受容体の画像診断方法である。 In another embodiment of the present invention, vasopressin V1b in the brain of an animal is characterized by administering an effective amount of a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof to the animal. This is a method for diagnostic imaging of a receptor.
また、本発明の他の１つの態様は、動物に一般式（Ｉ）に示される化合物又はその製薬学的に許容される塩を有効量投与することを特徴とする、動物におけるバソプレッシンＶ１ｂ受容体の発現した組織を用いた画像診断方法である。ここで、バソプレッシンＶ１ｂ受容体の発現した組織とは例えば脳スライス切片等が挙げられる。 In another embodiment of the present invention, the vasopressin V1b receptor in an animal is characterized by administering an effective amount of a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof to the animal. This is a diagnostic imaging method using a tissue in which the expression of the above occurs. Here, the tissue in which the vasopressin V1b receptor is expressed includes, for example, a brain slice section.
これらの態様は、別の側面では、一般式（Ｉ）に示される化合物又はその製薬学的に許容される塩を含む、バソプレッシンＶ１ｂ受容体に関連した疾患の診断薬に関する。 In another aspect, these embodiments relate to a diagnostic agent for diseases associated with the vasopressin V1b receptor, comprising a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof.
これらの方法又は診断薬は、バソプレッシンＶ１ｂ受容体に関連した疾患、例えば、気分障害、不安障害、統合失調症、アルツハイマー病、パーキンソン病、ハンチントン舞踏病、摂食障害、高血圧、消化器疾患、薬物依存症、てんかん、脳梗塞、脳虚血、脳浮腫、頭部外傷、炎症、免疫関連疾患、又は脱毛症の診断に有用である。 These methods or diagnostic agents are used for diseases related to vasopressin V1b receptor, such as mood disorders, anxiety disorders, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorders, hypertension, digestive disorders, drugs Useful in the diagnosis of addiction, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head trauma, inflammation, immune related diseases, or alopecia.
また、本発明の他の１つの態様は、動物に一般式（Ｉ）に示される化合物又はその製薬学的に許容される塩を有効量投与することを特徴とする、動物におけるバソプレッシンＶ１ｂ受容体の機能を検出又は定量化する方法である。 In another embodiment of the present invention, the vasopressin V1b receptor in an animal is characterized by administering an effective amount of a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof to the animal. This is a method for detecting or quantifying the function.
ここで、「動物」は、ヒトやサル等の哺乳動物を含み、好ましくはヒトである。 Here, the “animal” includes mammals such as humans and monkeys, preferably humans.
本発明の化合物は、バソプレッシンＶ１ｂ受容体が関与すると考えられている多様な病気においてバソプレッシンＶ１ｂ受容体結合リガンド（バソプレッシンＶ１ｂ受容体アゴニスト、アンタゴニスト、インバースアゴニスト等）の作用を評価することを目的とした臨床試験に使用することが可能である。例えば、バソプレッシンＶ１ｂ受容体調節剤の臨床評価を行うにあたって、脳内での当該薬物の受容体占有の程度を評価するためのトレーサー化合物（バソプレッシンＶ１ｂ受容体標識剤）としても利用可能である。 The compounds of the present invention are intended to evaluate the action of vasopressin V1b receptor binding ligands (vasopressin V1b receptor agonists, antagonists, inverse agonists, etc.) in various diseases thought to involve the vasopressin V1b receptor. It can be used for clinical trials. For example, when performing clinical evaluation of a vasopressin V1b receptor modulator, it can also be used as a tracer compound (vasopressin V1b receptor labeling agent) for evaluating the degree of receptor occupancy of the drug in the brain.
本発明の化合物は、例えば下記に示す方法に従って製造することができる。 The compound of the present invention can be produced, for example, according to the method shown below.
化合物（Ｉ）、（ＩＩ）及びそれらの製薬学的に許容される塩は、当業者に公知である種々の有機合成手法を用いて合成することができる。例えば、以下に製造法を示すが本合成法に限られたものではない。なお、以下の製造法の例示において、化合物は反応に支障にならない塩を形成していてもよい。
式（Ｉ）で表される化合物は、スキーム１に示す合成法で製造することができる。
Compounds (I), (II) and their pharmaceutically acceptable salts can be synthesized using various organic synthesis techniques known to those skilled in the art. For example, the production method is shown below, but is not limited to this synthesis method. In the following examples of production methods, the compound may form a salt that does not hinder the reaction.
The compound represented by the formula (I) can be produced by the synthesis method shown in Scheme 1.
（式中、Ｒ1、Ｒ2及びＸは前記と同義である。Ｌ1は脱離基を示す。脱離基とは、４−ニトロベンゼンスルホニルオキシ基、ｐ−トルエンスルホニルオキシ基、メタンスルホニルオキシ基、ハロゲン原子等を意味する。）
式（Ｉ）で表される化合物は、式（ＩＩ）で表される化合物と、式（１−ａ）で表される化合物とを反応させることにより得ることができる（工程１−１）。工程１−１における反応は、テトラヒドロフラン、アセトニトリル、Ｎ，Ｎ−ジメチルホルムアミド、ジメチルスルホキシド、水等の溶媒中、又はそれらの混合溶媒中、室温から溶媒の沸点付近の温度条件下、炭酸カリウム、炭酸セシウム、水酸化ナトリウム等の無機塩基や、トリエチルアミン、ジイソプロピルエチルアミン等の有機塩基の存在により、反応が進行する。
(In the formula, R 1 , R 2 and X are as defined above. L 1 represents a leaving group. The leaving group is a 4-nitrobenzenesulfonyloxy group, p-toluenesulfonyloxy group, methanesulfonyloxy. Group, halogen atom, etc.)
The compound represented by formula (I) can be obtained by reacting the compound represented by formula (II) with the compound represented by formula (1-a) (step 1-1). The reaction in Step 1-1 is carried out in a solvent such as tetrahydrofuran, acetonitrile, N, N-dimethylformamide, dimethyl sulfoxide, water, or a mixed solvent thereof under a temperature condition from room temperature to the boiling point of the solvent under the conditions of potassium carbonate, carbonic acid. The reaction proceeds due to the presence of an inorganic base such as cesium or sodium hydroxide, or an organic base such as triethylamine or diisopropylethylamine.
式（ＩＩ）で表される化合物は、スキーム２に示す合成法で製造することができる。 The compound represented by the formula (II) can be produced by the synthesis method shown in Scheme 2.
（式中、Ｒ1、Ｘは前記と同義である。Ｈａｌはハロゲン原子を示す。Ｌ2はフェノール性水酸基の保護基を示す［プロテクティブ グループス イン オーガニック シンセシス（Protective Groups in Organic Synthesis）第４版、ジョン ウィリー アンド サンズ（John Wiley & Sons, INC.） 参照］。Ｌ3は脱離基を示す。脱離基とは、ｐ−トルエンスルホニルオキシ基、メタンスルホニルオキシ基、ハロゲン原子等を意味する。）
式（２−ｂ）で表される化合物は式（２−ａ）で表される化合物をボロン酸誘導体とした後、過酸を用いてヒドロキシ化することにより得ることができる（工程２−１）。本工程は、ＷＯ２００６／０２１８８６号公報記載の方法に従って実施することができる。式（２−ｄ）で表される化合物は、工程２−２、工程２−３及び工程２−４の３つの異なる工程により、それぞれ製造することができる。すなわち、工程２−２は、式（２−ｂ）で表される化合物と式（２−ｃ）で表される化合物を反応させることにより得ることができる。式（２−ｃ）で表される化合物は塩を形成しても良い。工程２−２における反応は、工程１−１と同様の方法で行うことができる。また、式（２−ｄ）で表される化合物は、式（２−ｂ）で表される化合物と式（２−ｅ）で表される化合物を光延反応の条件下反応させて得ることができる（工程２−３）。光延反応に関する包括的概観はSynthesis. 1981, 1-28; Chem. Asian J. 2007, 2, 1340-1355.; Chem. Pharm. Bull. 2003, 51(4), 474-476に見出される。さらに、式（２−ｄ）で表される化合物は、式（２−ａ）で表される化合物と式（２−ｅ）で表される化合物をパラジウム触媒を用いたエーテル化反応の条件下反応させることにより得ることができる（工程２−４）。パラジウム触媒を用いたエーテル化反応に関する包括的概観は、M. Paulucki, J. P. Wolfe, S. L. Buchwald, J. Am. Chem. Soc., 1996, 118, 10333.; G. Mann, J. F. Hartwig, J. Am. Chem. Soc. 1996, 118, 13109.; M. Watanabe, M. Nishiyama, Y. Koie, Tetrahedron Lett. 1999, 40, 8837.; Q. Shelby, N. Kataoka, G. Mann, J. F. Hartwig, J. Am. Chem. Soc. 2000, 122, 10718.; K. E. Torraca, S. Kuwabe, S. L. Buchwald, J. Am. Chem. Soc. 2000, 122, 12907.; C. A. Parrish, S. L. Buchwald, J. Org. Chem. 2001, 66, 2498.; P. M. Karen, E. Torraca, X. Huang, C. A. Parrish, and S. L. Buchwald, J. Am. Chem. Soc, 2001, 10770-10771.; Andrei V. Vorogushin, Xiaohua Huang, and Stephen L. Buchwald J. Am. Chem. Soc., 2005, 8146 -8149.に見出される。式（ＩＩ）で表される化合物は式（２−ｄ）で表される化合物のＬ2基を、一般的手法にて脱保護する［プロテクティブ グループス イン オーガニック シンセシス（Protective Groups in Organic Synthesis）第４版、ジョン ウィリー アンド サンズ（John Wiley & Sons, INC.） 参照］ことにより得ることができる（工程２−５）。
(In the formula, R 1 and X are as defined above. Hal represents a halogen atom. L 2 represents a protecting group for a phenolic hydroxyl group [Protective Groups in Organic Synthesis, 4th edition] See John Wiley & Sons, Inc.] L 3 represents a leaving group, which means a p-toluenesulfonyloxy group, a methanesulfonyloxy group, a halogen atom, or the like. .)
The compound represented by the formula (2-b) can be obtained by converting the compound represented by the formula (2-a) into a boronic acid derivative and then hydroxylating with a peracid (Step 2-1). ). This step can be carried out according to the method described in WO2006 / 021886. The compound represented by the formula (2-d) can be produced by three different steps of Step 2-2, Step 2-3, and Step 2-4. That is, step 2-2 can be obtained by reacting the compound represented by formula (2-b) with the compound represented by formula (2-c). The compound represented by the formula (2-c) may form a salt. The reaction in step 2-2 can be carried out in the same manner as in step 1-1. The compound represented by the formula (2-d) can be obtained by reacting the compound represented by the formula (2-b) with the compound represented by the formula (2-e) under the conditions of Mitsunobu reaction. Yes (step 2-3). A comprehensive overview of the Mitsunobu reaction can be found in Synthesis. 1981, 1-28; Chem. Asian J. 2007, 2, 1340-1355 .; Chem. Pharm. Bull. 2003, 51 (4), 474-476. Furthermore, the compound represented by the formula (2-d) is obtained by subjecting the compound represented by the formula (2-a) and the compound represented by the formula (2-e) to the conditions for the etherification reaction using a palladium catalyst. It can be obtained by reacting (step 2-4). A comprehensive overview of palladium-catalyzed etherification reactions can be found in M. Paulucki, JP Wolfe, SL Buchwald, J. Am. Chem. Soc., 1996, 118, 10333 .; G. Mann, JF Hartwig, J. Am Chem. Soc. 1996, 118, 13109 .; M. Watanabe, M. Nishiyama, Y. Koie, Tetrahedron Lett. 1999, 40, 8837 .; Q. Shelby, N. Kataoka, G. Mann, JF Hartwig, J Am. Chem. Soc. 2000, 122, 10718 .; KE Torraca, S. Kuwabe, SL Buchwald, J. Am. Chem. Soc. 2000, 122, 12907 .; CA Parrish, SL Buchwald, J. Org. Chem 2001, 66, 2498 .; PM Karen, E. Torraca, X. Huang, CA Parrish, and SL Buchwald, J. Am. Chem. Soc, 2001, 10770-10771 .; Andrei V. Vorogushin, Xiaohua Huang, and Found in Stephen L. Buchwald J. Am. Chem. Soc., 2005, 8146 -8149. The compound represented by the formula (II) deprotects the L 2 group of the compound represented by the formula (2-d) by a general method [Protective Groups in Organic Synthesis] 4th edition, see John Wiley & Sons, INC.] (Step 2-5).
式（２−ａ）で表される化合物のうち、式（３−ｄ）で表される化合物はスキーム３に示す合成法で製造することができる。 Among the compounds represented by the formula (2-a), the compound represented by the formula (3-d) can be produced by the synthesis method shown in Scheme 3.
（式中、Ｒ1、Ｌ2、Ｘ、Ｈａｌは上記と同じである。Ｌ4はＣ1-5アルキルを示す。）
式（３−ｄ）で表される化合物は式（３−ａ）で表される化合物と、式（３−ｂ）で表されるアルデヒドを、脱水縮合させることにより１，２−ジヒドロピリドピリミジン−４−オン誘導体（３−ｃ）を得た後に（工程３−１）、引き続き酸化反応に付すことにより、得ることができる（工程３−２）。工程３−１における縮合反応は、酢酸等の有機酸存在下、エタノール、２−プロパノール等の溶媒中、反応溶媒の沸点付近の温度条件下進行し、モレキュラーシーブス等の脱水剤を用いて副生する水を除くことにより、より円滑に縮合反応は進行する。工程３−２における酸化反応は、活性二酸化マンガン等の酸化剤を用い、クロロホルム、Ｎ，Ｎ−ジメチルホルムアミド、テトラヒドロフラン等の溶媒中、又はそれらの混合溶媒中、室温から反応溶媒の沸点付近の温度条件下進行する。また、式（３−ｄ）で表される化合物は式（３−ａ）で表される化合物と式（３−ｅ）で表される化合物を、エタノール、２−プロパノール、テトラヒドロフラン等の溶媒中、反応溶媒の沸点付近の温度条件下縮合させ得ることができる（工程３−３）。
(In the formula, R 1 , L 2 , X and Hal are the same as above. L 4 represents C 1-5 alkyl.)
The compound represented by the formula (3-d) is obtained by subjecting the compound represented by the formula (3-a) and the aldehyde represented by the formula (3-b) to dehydration condensation, and 1,2-dihydropyrido After obtaining the pyrimidin-4-one derivative (3-c) (step 3-1), it can be obtained by subsequent oxidation (step 3-2). The condensation reaction in step 3-1 proceeds in the presence of an organic acid such as acetic acid in a solvent such as ethanol or 2-propanol under temperature conditions near the boiling point of the reaction solvent, and is a by-product using a dehydrating agent such as molecular sieves. By removing the water, the condensation reaction proceeds more smoothly. The oxidation reaction in Step 3-2 uses an oxidizing agent such as active manganese dioxide, and is in a solvent such as chloroform, N, N-dimethylformamide, tetrahydrofuran, or a mixed solvent thereof, from room temperature to a temperature near the boiling point of the reaction solvent. Progress under conditions. In addition, the compound represented by the formula (3-d) is obtained by mixing the compound represented by the formula (3-a) and the compound represented by the formula (3-e) in a solvent such as ethanol, 2-propanol, and tetrahydrofuran. , And can be condensed under temperature conditions near the boiling point of the reaction solvent (step 3-3).
以下、実施例と試験例を挙げて本発明を更に詳しく説明する。 Hereinafter, the present invention will be described in more detail with reference to Examples and Test Examples.
本発明は下記の実施例によって更に詳細に説明されるが、これら実施例は本発明を限定するものではなく、また、本発明の範囲を逸脱しない範囲で変化させてもよい。 The present invention will be described in more detail with reference to the following examples. However, these examples do not limit the present invention, and may be changed without departing from the scope of the present invention.
実施例中記載の各機器データは以下の測定機器で測定した。
ＭＳスペクトル：Ａｇｉｌｅｎｔ ６１５０／Ａｇｉｌｅｎｔ １２９０Ｉｎｆｉｎｉｔｙ
ＮＭＲスペクトル：［1Ｈ-ＮＭＲ］ＪＮＭ−ＥＣＡ６００（日本電子）
実施例中で使用した略語を以下に示す。
ＭＳ（質量分析）、ＡＰＣＩ（大気圧化学イオン化）、ＥＳＩ（エレクトロスプレーイオン化）。
Each instrument data described in the examples was measured with the following measuring instruments.
MS spectrum: Agilent 6150 / Agilent 1290 Infinity
NMR spectrum: [ 1 H-NMR] JNM-ECA600 (JEOL)
Abbreviations used in the examples are shown below.
MS (mass spectrometry), APCI (atmospheric pressure chemical ionization), ESI (electrospray ionization).
実施例Ａ−１：Ｎ−ｔｅｒｔ−ブチル−２−［２−（３−11Ｃ−メトキシフェニル）−６−［３−（モルホリン−４−イル）プロポキシ］−４−オキソピリド［２，３−ｄ］ピリミジン−３（４Ｈ）−イル］アセトアミド（Ａ−１）の合成 Example A-1: N-tert- Butyl-2-[2-(3-11 C-methoxyphenyl) -6- [3- (morpholin-4-yl) propoxy] -4-oxopyrido [2,3 d] Synthesis of pyrimidine-3 (4H) -yl] acetamide (A-1)
（１）２−［６−ブロモ−２−（３−メトキシフェニル）−４−オキソ−１，４−ジヒドロピリド［２，３−ｄ］ピリミジン−３（２Ｈ）−イル］−Ｎ−ｔｅｒｔ−ブチルアセトアミド（Ａ−１−１）の合成 (1) 2- [6-Bromo-2- (3-methoxyphenyl) -4-oxo-1,4-dihydropyrido [2,3-d] pyrimidin-3 (2H) -yl] -N-tert-butyl Synthesis of acetamide (A-1-1)
窒素気流下、２−アミノ−５−ブロモ−Ｎ−［２−（ｔｅｒｔ−ブチルアミノ）−２−オキソエチル］ニコチンアミド（２５．０ｇ）、３−メトキシベンズアルデヒド（３１．０ｇ）、酢酸（２２．８ｇ）のＥｔＯＨ（５００ｍＬ）懸濁液をディーン・スターク装置で脱水しながら５時間加熱還流した。放冷後、減圧下で反応溶媒を留去し、得られた残渣にＥｔＯＡｃを加え、生じた固体をろ取、乾燥し表題化合物（３３．４ｇ、無色固体）を得た。
MS (ESI neg.) m/z : 445([M-H]-).
Under a nitrogen stream, 2-amino-5-bromo-N- [2- (tert-butylamino) -2-oxoethyl] nicotinamide (25.0 g), 3-methoxybenzaldehyde (31.0 g), acetic acid (22. A suspension of 8 g) of EtOH (500 mL) was heated to reflux for 5 hours while dewatering with a Dean-Stark apparatus. After allowing to cool, the reaction solvent was evaporated under reduced pressure, EtOAc was added to the resulting residue, and the resulting solid was collected by filtration and dried to give the title compound (33.4 g, colorless solid).
MS (ESI neg.) M / z: 445 ([MH] - ).
（２）２−［６−ブロモ−２−（３−メトキシフェニル）−４−オキソピリド［２，３−ｄ］ピリミジン−３（４Ｈ）−イル］−Ｎ−ｔｅｒｔ−ブチルアセトアミド（Ａ−１−２）の合成 (2) 2- [6-Bromo-2- (3-methoxyphenyl) -4-oxopyrido [2,3-d] pyrimidin-3 (4H) -yl] -N-tert-butylacetamide (A-1- 2) Synthesis
窒素気流下、実施例Ａ−１（１）で得られた化合物Ａ−１−１（３３．０ｇ）、ＭｎＯ2（３２．１ｇ）のＴＨＦ（５１２ｍＬ）、ＣＨＣｌ3（１３０ｍＬ）懸濁液を５時間加熱還流した。熱時セライト（登録商標）を用いてろ過後、ＴＨＦ（６００ｍＬ）にて洗浄し、ろ液を減圧下で濃縮した。得られた残渣にＥｔＯＡｃを加え、生じた固体をろ取、乾燥し表題化合物（２８．７ｇ、無色固体）得た。
MS (ESI pos.) m/z : 445([M+H]+).
Under a nitrogen stream, a suspension of compound A-1-1 (33.0 g) obtained in Example A-1 (1), MnO 2 (32.1 g) in THF (512 mL) and CHCl 3 (130 mL) was added. The mixture was heated to reflux for 5 hours. After filtration using hot Celite (registered trademark), the filtrate was washed with THF (600 mL), and the filtrate was concentrated under reduced pressure. EtOAc was added to the obtained residue, and the resulting solid was collected by filtration and dried to give the title compound (28.7 g, colorless solid).
MS (ESI pos.) M / z: 445 ([M + H] + ).
（３）Ｎ−ｔｅｒｔ−ブチル−２−［６−ヒドロキシ−２−（３−メトキシフェニル）−４−オキソピリド［２，３−ｄ］ピリミジン−３（４Ｈ）−イル］アセトアミド（Ａ−１−３）の合成 (3) N-tert-butyl-2- [6-hydroxy-2- (3-methoxyphenyl) -4-oxopyrido [2,3-d] pyrimidin-3 (4H) -yl] acetamide (A-1- 3) Synthesis
窒素気流下、実施例Ａ−１（２）で得られた化合物Ａ−１−２（４．４５ｇ）、４，４，４’，４’，５，５，５’，５’−オクタメチル−２，２’−ビ−１，３，２−ジオキサボロラン（５．０８ｇ）、ＰｄＣｌ2（ｄｐｐｆ）・ＣＨ2Ｃｌ2（４０８ｍｇ）及びＡｃＯＫ（２．９４ｇ）のＤＭＳＯ（４５ｍＬ）溶液を１００℃にて２時間加熱攪拌した。放冷後、水（２００ｍＬ）を加え、生じた固体をろ取、乾燥し固体（９．９１ｇ、茶褐色固体）を得た。得られた固体（９．９１ｇ）のＴＨＦ（２５ｍＬ）及びＥｔＯＨ（２５ｍＬ）溶液にＮａＨＣＯ3水溶液（１．６８ｇ／水 １５ｍＬ）を加えた後に氷冷し、反応液温度８℃以下を保ちながら、３０％過酸化水素水（３．４０ｍＬ）を加えた後、２時間攪拌した。反応液に亜硫酸ナトリウム水溶液（３．７８ｇ／水 ５０ｍＬ）を加えた後、１５分間攪拌した。ＣＨＣｌ3（１００ｍＬ）、飽和食塩水（１００ｍＬ）を加え分液後、水層をＣＨＣｌ3（５０ｍＬ）で２回抽出した。有機層を合わせてＮａ2ＳＯ4で乾燥後に乾燥剤をろ別し、ろ液を減圧下で濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ＳＮＡＰ Ｃａｒｔｒｉｄｇｅ ＨＰ−Ｓｐｈｅｒｅ、移動相：ＣＨＣｌ3／ＭｅＯＨ＝１００／０〜９０／１０；ｖ／ｖ）にて精製し表題化合物（３．６９ｇ、灰色固体）を得た。
MS (ESI pos.) m/z : 383([M+H]+).
Under a nitrogen stream, compound A-1-2 (4.45 g) obtained in Example A-1 (2), 4,4,4 ′, 4 ′, 5,5,5 ′, 5′-octamethyl- A solution of 2,2′-bi-1,3,2-dioxaborolane (5.08 g), PdCl 2 (dppf) .CH 2 Cl 2 (408 mg) and AcOK (2.94 g) in DMSO (45 mL) was brought to 100 ° C. And stirred for 2 hours. After allowing to cool, water (200 mL) was added, and the resulting solid was collected by filtration and dried to obtain a solid (9.91 g, brown solid). An aqueous solution of NaHCO 3 (1.68 g / 15 mL of water) was added to a solution of the obtained solid (9.91 g) in THF (25 mL) and EtOH (25 mL), and then ice-cooled, while maintaining the reaction solution temperature at 8 ° C. or lower, After adding 30% aqueous hydrogen peroxide (3.40 mL), the mixture was stirred for 2 hours. An aqueous sodium sulfite solution (3.78 g / 50 mL of water) was added to the reaction solution, and the mixture was stirred for 15 minutes. CHCl 3 (100 mL) and saturated brine (100 mL) were added for liquid separation, and the aqueous layer was extracted twice with CHCl 3 (50 mL). The organic layers were combined and dried over Na 2 SO 4 , the desiccant was filtered off, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (SNAP Cartridge HP-Sphere, mobile phase: CHCl 3 / MeOH = 100/0 to 90/10; v / v) to give the title compound (3.69 g, gray solid) Got.
MS (ESI pos.) M / z: 383 ([M + H] + ).
（４）Ｎ−ｔｅｒｔ−ブチル−２−［２−（３−メトキシフェニル）−６−［３−（モルホリン−４−イル）プロポキシ］−４−オキソピリド［２，３−ｄ］ピリミジン−３（４Ｈ）−イル］アセトアミド（Ａ−１−４）の合成 (4) N-tert-butyl-2- [2- (3-methoxyphenyl) -6- [3- (morpholin-4-yl) propoxy] -4-oxopyrido [2,3-d] pyrimidine-3 ( 4H) -yl] acetamide (A-1-4)
実施例Ａ−１（３）で得られた化合物Ａ−１−３（３．６５ｇ）、４−（３−クロロプロピル）モルホリン 塩酸塩（２．２９ｇ）、炭酸セシウム（１５．６ｇ）及びヨウ化カリウム（０．７９２ｇ）のＤＭＦ（３６ｍＬ）懸濁液を外温８５℃で４時間攪拌した。反応液を放冷後、飽和ＮａＨＣＯ3水溶液（１２０ｍＬ）、ＥｔＯＡｃ（１２０ｍＬ）及びトルエン（２０ｍＬ）を加え分液後、有機層を飽和食塩水（１２０ｍＬ）で洗浄した。水層をＥｔＯＡｃ（１２０ｍＬ）及びトルエン（２０ｍＬ）で２回抽出し、有機層を合わせてＮａ2ＳＯ4で乾燥した。乾燥剤をろ別後、ろ液を減圧下で濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ＳＮＡＰ Ｃａｒｔｒｉｄｇｅ ＨＰ−Ｓｐｈｅｒｅ、移動相：ＣＨＣｌ3／ＭｅＯＨ＝９９／１〜９０／１０；ｖ／ｖ）にて精製し表題化合物（４．５５ｇ、褐色アモルファス）を得た。
MS (ESI pos.) m/z : 510([M+H]+).
1H-NMR (600 MHz, CDCl3) δ (ppm) ; 1.35 (9 H, s), 2.01 - 2.08 (2 H, m), 2.48 (4 H, br. s.), 2.55 (2 H, t, J=7.0 Hz), 3.73 (4 H, t, J=4.5 Hz), 3.83 (3 H, s), 4.19 (2 H, t, J=6.4 Hz), 4.52 (2 H, s), 5.45 (1 H, s), 7.02 - 7.05 (1 H, m), 7.23 (1 H, d, J=7.4 Hz), 7.25 - 7.26 (1 H, m), 7.37 (1 H, t, J=7.8 Hz), 7.95 (1 H, d, J=3.3 Hz), 8.72 (1 H, d, J=3.3 Hz).
Compound A-1-3 (3.65 g), 4- (3-chloropropyl) morpholine hydrochloride (2.29 g), cesium carbonate (15.6 g) and iodine obtained in Example A-1 (3) A suspension of potassium fluoride (0.792 g) in DMF (36 mL) was stirred at an external temperature of 85 ° C. for 4 hours. The reaction mixture was allowed to cool, saturated aqueous NaHCO 3 solution (120 mL), EtOAc (120 mL) and toluene (20 mL) were added and separated, and the organic layer was washed with saturated brine (120 mL). The aqueous layer was extracted twice with EtOAc (120 mL) and toluene (20 mL), and the combined organic layers were dried over Na 2 SO 4 . After the desiccant was filtered off, the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (SNAP Cartridge HP-Sphere, mobile phase: CHCl 3 / MeOH = 99/1 to 90/10; v / v) to give the title compound (4.55 g, brown amorphous) Got.
MS (ESI pos.) M / z: 510 ([M + H] + ).
1 H-NMR (600 MHz, CDCl 3 ) δ (ppm); 1.35 (9 H, s), 2.01-2.08 (2 H, m), 2.48 (4 H, br.s.), 2.55 (2 H, t, J = 7.0 Hz), 3.73 (4 H, t, J = 4.5 Hz), 3.83 (3 H, s), 4.19 (2 H, t, J = 6.4 Hz), 4.52 (2 H, s), 5.45 (1 H, s), 7.02-7.05 (1 H, m), 7.23 (1 H, d, J = 7.4 Hz), 7.25-7.26 (1 H, m), 7.37 (1 H, t, J = 7.8 Hz), 7.95 (1 H, d, J = 3.3 Hz), 8.72 (1 H, d, J = 3.3 Hz).
（５）Ｎ−ｔｅｒｔ−ブチル−２−［２−（３−ヒドロキシフェニル）−６−［３−（モルホリン−４−イル）プロポキシ］−４−オキソピリド［２，３−ｄ］ピリミジン−３（４Ｈ）−イル］アセトアミド（プレカーサーＡ）の合成
の合成
(5) N-tert-butyl-2- [2- (3-hydroxyphenyl) -6- [3- (morpholin-4-yl) propoxy] -4-oxopyrido [2,3-d] pyrimidine-3 ( Synthesis of the synthesis of 4H) -yl] acetamide (Precursor A)
実施例Ａ−１（４）で得られた化合物Ａ−１−４（１．００ｇ）をＣＨＣｌ3（２０ｍＬ）に溶解し、氷冷下でＢＢｒ3（１ｍｍｏｌ／Ｌジクロロメタン溶液、９．８１ｍＬ）を滴下し室温で２４時間攪拌した。反応液に氷冷下でＭｅＯＨを加えた後に、ＣＨＣｌ3（８０ｍＬ）、飽和ＮａＨＣＯ3水溶液（１００ｍＬ）を加え分液後、有機層を飽和食塩水（１００ｍＬ）で洗浄した。水層をＣＨＣｌ3（１００ｍＬ）で２回抽出し有機層を合わせてＮａ2ＳＯ4で乾燥した。乾燥剤をろ別後、ろ液を減圧下で濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ＳＮＡＰ Ｃａｒｔｒｉｄｇｅ ＫＰ-ＮＨ、移動相：ＣＨＣｌ3／ＭｅＯＨ＝１００／０〜９０／１０；ｖ／ｖ）にて精製した。得られた粗精製物にＥｔＯＡｃ（１．５ｍＬ）及びｎ−ヘキサン（１．５ｍＬ）を加え、１０分間加熱還流後に、室温まで冷却し、１２時間攪拌した。固体をろ取、乾燥し、表題化合物（４００ｍｇ、淡褐色固体）を得た。
MS (ESI pos.) m/z : 496([M+H]+).
1H-NMR (600 MHz, CDCl3) δ (ppm) ; 1.32 (9 H, s), 2.01 - 2.07 (2 H, m), 2.42 - 2.51 (4 H, m), 2.54 (2 H, t, J=6.8 Hz), 3.73 (4 H, t, J=4.3 Hz), 4.15 - 4.20 (2 H, m), 4.51 (2 H, s), 5.48 (1 H, s), 6.89 - 6.93 (1 H, m), 7.06 (1 H, d, J=7.4 Hz), 7.12 - 7.15 (1 H, m), 7.24 (1 H, t, J=7.8 Hz), 7.93 - 7.97 (1 H, m), 8.39 (1 H, br. s.), 8.66 (1 H, d, J=3.3 Hz).
Compound A-1-4 (1.00 g) obtained in Example A-1 (4) was dissolved in CHCl 3 (20 mL), and BBr 3 (1 mmol / L dichloromethane solution, 9.81 mL) was cooled with ice. Was added dropwise and stirred at room temperature for 24 hours. MeOH was added to the reaction solution under ice-cooling, CHCl 3 (80 mL) and saturated aqueous NaHCO 3 solution (100 mL) were added to separate the solution, and the organic layer was washed with saturated brine (100 mL). The aqueous layer was extracted twice with CHCl 3 (100 mL), and the organic layers were combined and dried over Na 2 SO 4 . After the desiccant was filtered off, the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (SNAP Cartridge KP-NH, mobile phase: CHCl 3 / MeOH = 100/0 to 90/10; v / v). EtOAc (1.5 mL) and n-hexane (1.5 mL) were added to the obtained crude product, and the mixture was heated to reflux for 10 minutes, cooled to room temperature, and stirred for 12 hours. The solid was collected by filtration and dried to give the title compound (400 mg, light brown solid).
MS m / z (ESI pos. ): 496 ([M + H] +).
1 H-NMR (600 MHz, CDCl 3 ) δ (ppm); 1.32 (9 H, s), 2.01-2.07 (2 H, m), 2.42-2.51 (4 H, m), 2.54 (2 H, t , J = 6.8 Hz), 3.73 (4 H, t, J = 4.3 Hz), 4.15-4.20 (2 H, m), 4.51 (2 H, s), 5.48 (1 H, s), 6.89-6.93 ( 1 H, m), 7.06 (1 H, d, J = 7.4 Hz), 7.12-7.15 (1 H, m), 7.24 (1 H, t, J = 7.8 Hz), 7.93-7.97 (1 H, m ), 8.39 (1 H, br.s.), 8.66 (1 H, d, J = 3.3 Hz).
（６）Ｎ−ｔｅｒｔ−ブチル−２−［２−（３−11Ｃ−メトキシフェニル）−６−［３−（モルホリン−４−イル）プロポキシ］−４−オキソピリド［２，３−ｄ］ピリミジン−３（４Ｈ）−イル］アセトアミド（Ａ−１）の合成 (6) N-tert-butyl-2-[2-(3-11 C-methoxyphenyl) -6- [3- (morpholin-4-yl) propoxy] -4-oxopyrido [2,3-d] pyrimidine -3 (4H) -yl] acetamide (A-1)
化合物Ａ−1は、プレカーサーＡのフェノール部分の酸素原子をサイクロトロン装置により製造した［11Ｃ］ヨウ化メチルを用いてアルキル化することにより合成した。 Compound A-1 was synthesized by alkylating the oxygen atom of the phenol moiety of precursor A with [ 11 C] methyl iodide produced by a cyclotron apparatus.
１８．０ＭｅＶの陽子を用いて14Ｎ（Ｐ，α）11Ｃ反応に従って窒素を２０μＡのビームカレントを用いて１５分照射することにより炭素−１１を製造した。標的ガス中の少量の酸素（５ｐｐｍ）の存在により炭素−１１は［11Ｃ］二酸化炭素に変換された。得られた［11Ｃ］二酸化炭素を水素化リチウムアルミニウムを用いて還元し、続いてヨウ化水素酸と反応させることにより［11Ｃ］ヨウ化メチルを合成した。 Carbon-11 was produced by irradiating with nitrogen at 20 μA for 15 minutes according to the 14 N (P, α) 11 C reaction using 18.0 MeV protons. Carbon-11 was converted to [ 11 C] carbon dioxide by the presence of a small amount of oxygen (5 ppm) in the target gas. The obtained [ 11 C] carbon dioxide was reduced using lithium aluminum hydride, and subsequently reacted with hydroiodic acid to synthesize [ 11 C] methyl iodide.
プレカーサーＡ（１．０ｍｇ）、水酸化ナトリウム水溶液（０．５ｍｏｌ／Ｌ、５μＬ）及び無水Ｎ，Ｎ−ジメチルホルムアミド（３００μＬ）の混合物をよく振り混ぜて混和した。反応混合物を−２０℃に冷却し、［11Ｃ］ヨウ化メチルを吹き込み、その後８０℃で５分間加熱した。反応混合物にアセトニトリル／水／トリエチルアミン（４０／６０／０．１）溶液（１ｍＬ）を加え、分取ＨＰＬＣカラム（ＳＨＩＳＥＩＤＯ ＣＡＰＣＥＬＬ ＰＡＣ Ｃ−１８ ２５０×１０ ｍｍ）に注入し、５ｍＬ／分の流量でアセトニトリル／水／トリエチルアミン（４０／６０／０．１）溶液により溶出した。８〜９分後に溶出され丸底フラスコに集められた化合物Ａを含む放射活性フラクションを、減圧下エアヒーターで１００℃に加熱して蒸発乾固させた。残渣を生理食塩水（３ｍＬ）に溶解し、滅菌したバイアル瓶に集めた。品質管理はアセトニトリル／水／トリエチルアミン（４０／６０／０．１）溶液を移動相として、１ｍＬ／分の流量で分析的ＨＰＬＣ（ＳＨＩＳＥＩＤＯ ＣＡＰＣＥＬＬ ＰＡＣ Ｃ−１８ ２５０×４．６ ｍｍ）を用いて行った。当該標識体の保持時間と非標識体の保持時間が同等であることを確認した。 A mixture of Precursor A (1.0 mg), aqueous sodium hydroxide (0.5 mol / L, 5 μL) and anhydrous N, N-dimethylformamide (300 μL) was well shaken and mixed. The reaction mixture was cooled to −20 ° C., blown with [ 11 C] methyl iodide and then heated at 80 ° C. for 5 minutes. Acetonitrile / water / triethylamine (40/60 / 0.1) solution (1 mL) was added to the reaction mixture and injected into a preparative HPLC column (SHISEIDO CAPCELL PAC C-18 250 × 10 mm) at a flow rate of 5 mL / min. Elution with acetonitrile / water / triethylamine (40/60 / 0.1) solution. The radioactive fraction containing Compound A eluted after 8-9 minutes and collected in a round bottom flask was heated to 100 ° C. with an air heater under reduced pressure to evaporate to dryness. The residue was dissolved in physiological saline (3 mL) and collected in a sterile vial. Quality control was performed using analytical HPLC (SHISEIDO CAPCELL PAC C-18 250 × 4.6 mm) at a flow rate of 1 mL / min using acetonitrile / water / triethylamine (40/60 / 0.1) solution as a mobile phase. It was. It was confirmed that the retention time of the labeled body was the same as that of the non-labeled body.
本製造により、収量２．１０ＧＢｑ〜３．２４ＧＢｑ、放射化学的純度９８％以上、比放射能４５〜８９ＧＢｑ／μｍｏｌの化合物Ａ−１が得られた。ＨＰＬＣ精製および調剤を含む平均全合成時間は、照射の終了から約２８分であった。 By this production, Compound A-1 having a yield of 2.10 GBq to 3.24 GBq, a radiochemical purity of 98% or more and a specific activity of 45 to 89 GBq / μmol was obtained. The average total synthesis time including HPLC purification and formulation was about 28 minutes from the end of irradiation.
実施例Ｂ−１：Ｎ−ｔｅｒｔ−ブチル−２−［２−（６−11Ｃ−メチルオキシピリジン−２−イル）−６−［３−（モルホリン−４−イル）プロポキシ］−４−オキソピリド［２，３−ｄ］ピリミジン−３（４Ｈ）−イル］アセトアミド（Ｂ−１）の合成 Example B-1: N-tert- Butyl-2- [2-(6- 11 C-methyloxy-2-yl) -6- [3- (morpholin-4-yl) propoxy] -4-oxopyrido Synthesis of [2,3-d] pyrimidin-3 (4H) -yl] acetamide (B-1)
（１）２−［６−ブロモ−２−（６−メトキシピリジン−２−イル）−４−オキソ−１，４−ジヒドロピリド［２，３−ｄ］ピリミジン−３（２Ｈ）−イル］−Ｎ−ｔｅｒｔ−ブチルアセトアミド（Ｂ−１−１）の合成 (1) 2- [6-Bromo-2- (6-methoxypyridin-2-yl) -4-oxo-1,4-dihydropyrido [2,3-d] pyrimidin-3 (2H) -yl] -N Synthesis of tert-butylacetamide (B-1-1)
実施例Ａ−１（１）と同様の手法にて、６−メトキシピリジン−２−カルバルデヒド（５．０ｇ）から表題化合物（８．２８ｇ）を得た。 In the same manner as in Example A-1 (1), the title compound (8.28 g) was obtained from 6-methoxypyridine-2-carbaldehyde (5.0 g).
（２）２−［６−ブロモ−２−（６−メトキシピリジン−２−イル）−４−オキソピリド［２，３−ｄ］ピリミジン−３（４Ｈ）−イル］−Ｎ−ｔｅｒｔ−ブチルアセトアミド（Ｂ−１−２）の合成 (2) 2- [6-Bromo-2- (6-methoxypyridin-2-yl) -4-oxopyrido [2,3-d] pyrimidin-3 (4H) -yl] -N-tert-butylacetamide ( Synthesis of B-1-2)
実施例Ａ−１（２）と同様の手法にて、実施例Ｂ−１（１）で得られた化合物Ｂ−１−１（８．２８ｇ）から表題化合物（６．８６ｇ、無色固体）を得た。
MS (ESI pos.) m/z : 446([M+H]+).
In the same manner as in Example A-1 (2), the title compound (6.86 g, colorless solid) was obtained from compound B-1-1 (8.28 g) obtained in Example B-1 (1). Obtained.
MS (ESI pos.) M / z: 446 ([M + H] + ).
（３）Ｎ−ｔｅｒｔ−ブチル−２−［６−ヒドロキシ−２−（６−メトキシピリジン−２−イル）−４−オキソピリド［２，３−ｄ］ピリミジン−３（４Ｈ）−イル］アセトアミド（Ｂ−１−３）の合成 (3) N-tert-butyl-2- [6-hydroxy-2- (6-methoxypyridin-2-yl) -4-oxopyrido [2,3-d] pyrimidin-3 (4H) -yl] acetamide ( Synthesis of B-1-3)
実施例Ａ−１（３）と同様の手法にて、実施例Ｂ−１（２）で得られた化合物Ｂ−１−２（６．２２ｇ）から表題化合物（３．８５ｇ、灰色固体）を得た。
MS (ESI pos.) m/z : 384([M+H]+).
In the same manner as in Example A-1 (3), the title compound (3.85 g, gray solid) was obtained from compound B-1-2 (6.22 g) obtained in Example B-1 (2). Obtained.
MS (ESI pos.) M / z: 384 ([M + H] + ).
（４）Ｎ−ｔｅｒｔ−ブチル−２−［２−（６−メトキシピリジン−２−イル）−６−［３−（モルホリン−４−イル）プロポキシ］−４−オキソピリド［２，３−ｄ］ピリミジン−３（４Ｈ）−イル］アセトアミド（Ｂ−１−４）の合成 (4) N-tert-butyl-2- [2- (6-methoxypyridin-2-yl) -6- [3- (morpholin-4-yl) propoxy] -4-oxopyrido [2,3-d] Synthesis of pyrimidine-3 (4H) -yl] acetamide (B-1-4)
実施例Ａ−１（４）と同様の手法にて、実施例Ｂ−１（３）で得られた化合物Ｂ−１−３（１．８０ｇ）から表題化合物（１．３１ｇ、黄色アモルファス）を得た。
MS (ESI pos.) m/z : 511([M+H]+).
1H-NMR (600 MHz, CDCl3) δ (ppm) ; 1.24 (9 H, s), 2.01 - 2.09 (2 H, m), 2.48 (4 H, br. s.), 2.55 (2 H, t, J=7.0 Hz), 3.70 - 3.77 (4 H, m), 3.94 (3 H, s), 4.20 (2 H, t, J=6.2 Hz), 5.08 (2 H, s), 5.39 (1 H, s), 6.87 (1 H, d, J=8.3 Hz), 7.67 - 7.71 (1 H, m), 7.72 - 7.77 (1 H, m), 7.96 (1 H, d, J=3.3 Hz), 8.73 (1 H, d, J=3.3 Hz).
In the same manner as in Example A-1 (4), the title compound (1.31 g, yellow amorphous) was obtained from compound B-1-3 (1.80 g) obtained in Example B-1 (3). Obtained.
MS (ESI pos.) M / z: 511 ([M + H] + ).
1 H-NMR (600 MHz, CDCl 3 ) δ (ppm); 1.24 (9 H, s), 2.01-2.09 (2 H, m), 2.48 (4 H, br.s.), 2.55 (2 H, t, J = 7.0 Hz), 3.70-3.77 (4 H, m), 3.94 (3 H, s), 4.20 (2 H, t, J = 6.2 Hz), 5.08 (2 H, s), 5.39 (1 H, s), 6.87 (1 H, d, J = 8.3 Hz), 7.67-7.71 (1 H, m), 7.72-7.77 (1 H, m), 7.96 (1 H, d, J = 3.3 Hz) , 8.73 (1 H, d, J = 3.3 Hz).
（５）Ｎ−ｔｅｒｔ−ブチル−２−［２−（６−ヒドロキシピリジン−２−イル）−６−［３−（モルホリン−４−イル）プロポキシ］−４−オキソピリド［２，３−ｄ］ピリミジン−３（４Ｈ）−イル］アセトアミド（プレカーサーＢ）の合成 (5) N-tert-butyl-2- [2- (6-hydroxypyridin-2-yl) -6- [3- (morpholin-4-yl) propoxy] -4-oxopyrido [2,3-d] Synthesis of pyrimidine-3 (4H) -yl] acetamide (precursor B)
実施例Ｂ−１（４）で得られた化合物Ｂ−１−４（７００ｍｇ）、ヨウ化ナトリウム（１．４４ｇ）をアセトニトリル（２０ｍＬ）に懸濁し、クロロトリメチルシラン（１．２１ｍＬ）を加えた。１５分間室温で攪拌後、外温８５℃で１時間攪拌した。反応液を放冷後、氷冷下で水（２０ｍＬ）を加えた後、飽和ＮａＨＣＯ3水溶液（１００ｍＬ）及びＣＨＣｌ3（１００ｍＬ）を加え分液後、有機層を飽和食塩水（１００ｍＬ）で洗浄した。水層をＣＨＣｌ3（１００ｍＬ）で３回抽出し、有機層を合わせてＮａ2ＳＯ4乾燥後、乾燥剤を濾別し、溶媒を減圧下留去した。得られた残渣をシリカゲルカラムクロマトグラフィー（ＳＮＡＰ Ｃａｒｔｒｉｄｇｅ ＨＰ-Ｓｐｈｅｒｅ、移動相：ＣＨＣｌ3／ＭｅＯＨ＝９８／２〜８５／１５；ｖ／ｖ）にて精製した。得られた粗精製物にＥｔＯＡｃ（６ｍＬ）及びｎ−ヘキサン（３ｍＬ）を加え、析出物をろ取、乾燥し、表題化合物（２９０ｍｇ、淡褐色アモルファス）を得た。
MS (ESI pos.) m/z : 497([M+H]+).
1H-NMR (600 MHz, CDCl3) δ (ppm) ; 1.41 (9 H, s), 1.99 - 2.09 (2 H, m), 2.48 (4 H, br. s.), 2.55 (2 H, t, J=6.8 Hz), 3.69 - 3.76 (4 H, m), 4.20 (2 H, t, J=6.2 Hz), 4.61 (2 H, s), 6.09 (1 H, s), 6.73 (1 H, d, J=8.3 Hz), 6.96 (1 H, d, J=6.6 Hz), 7.48 - 7.54 (1 H, m), 7.87 - 7.93 (1 H, m), 8.74 (1 H, d, J=3.3 Hz), 10.54 - 11.09 (1 H, m).
Compound B-1-4 (700 mg) obtained in Example B-1 (4) and sodium iodide (1.44 g) were suspended in acetonitrile (20 mL), and chlorotrimethylsilane (1.21 mL) was added. . After stirring at room temperature for 15 minutes, the mixture was stirred at an external temperature of 85 ° C. for 1 hour. After allowing the reaction solution to cool, water (20 mL) was added under ice-cooling, saturated aqueous NaHCO 3 solution (100 mL) and CHCl 3 (100 mL) were added, and the mixture was separated, and the organic layer was washed with saturated brine (100 mL). did. The aqueous layer was extracted three times with CHCl 3 (100 mL), the organic layers were combined and dried over Na 2 SO 4 , the desiccant was filtered off, and the solvent was evaporated under reduced pressure. The obtained residue was purified by silica gel column chromatography (SNAP Cartridge HP-Sphere, mobile phase: CHCl 3 / MeOH = 98/2 to 85/15; v / v). EtOAc (6 mL) and n-hexane (3 mL) were added to the resulting crude product, and the precipitate was collected by filtration and dried to give the title compound (290 mg, light brown amorphous).
MS (ESI pos.) M / z: 497 ([M + H] + ).
1 H-NMR (600 MHz, CDCl 3 ) δ (ppm); 1.41 (9 H, s), 1.99-2.09 (2 H, m), 2.48 (4 H, br.s.), 2.55 (2 H, t, J = 6.8 Hz), 3.69-3.76 (4 H, m), 4.20 (2 H, t, J = 6.2 Hz), 4.61 (2 H, s), 6.09 (1 H, s), 6.73 (1 H, d, J = 8.3 Hz), 6.96 (1 H, d, J = 6.6 Hz), 7.48-7.54 (1 H, m), 7.87-7.93 (1 H, m), 8.74 (1 H, d, J = 3.3 Hz), 10.54-11.09 (1 H, m).
（６）Ｎ−ｔｅｒｔ−ブチル−２−［２−（６−11Ｃ−メチルオキシピリジン−２−イル）−６−［３−（モルホリン−４−イル）プロポキシ］−４−オキソピリド［２，３−ｄ］ピリミジン−３（４Ｈ）−イル］アセトアミド（Ｂ−１）の合成 (6) N-tert-butyl-2- [2-(6- 11 C-methyloxy-2-yl) -6- [3- (morpholin-4-yl) propoxy] -4-oxopyrido [2, Synthesis of 3-d] pyrimidin-3 (4H) -yl] acetamide (B-1)
（方法１）
実施例Ｂ−１−（５）で得られたプレカーサーＢ (1.0 mg)と炭酸セシウム（10.0 mg）をジメチルスルホキシド（300 μL）に懸濁し、35.5 GBqの[11C]CO2から誘導した[11C]CH3Iを室温にて吹き込んだ。次いで100℃にて3分間加熱した。反応物を放冷後、溶媒 (50 mmol/L リン酸水溶液：アセトニトリル＝4:1) を1 ml加え、HPLCを用いて精製した。HPLCカラムはX-Terra C18 (250×10 mm)を用い、移動相は50 mmol/Lリン酸水溶液とアセトニトリルの体積比が4:1である溶媒を用い、流速は4 ml/minで行った。11分から12分に溶出したフラクションを25% アスコルビン酸 (100 μL)とTween 80/エタノール混合溶媒 (100 μL)を加えたなすフラスコに分取した後、減圧濃縮を行った。次いで0.5 mMリン酸ナトリウム補正液(1 ml)と注射用水(2 ml)の混合溶液にて再溶解を行い、0.81 GBqの表題化合物を含む溶液を得た。分析HPLCにて当該標識体の保持時間と非標識体の保持時間が同等であることを確認した。HPLCカラムはX-Terra C18 (150×4.6 mm)を用い、移動相は50 mmol/Lリン酸水溶液とアセトニトリルの体積比が4:1である溶媒を用い、流速は1 ml/minで行った。
（方法２）
実施例Ｂ−１−（５）で得られたプレカーサーＢ (1.0 mg)と炭酸カリウム（10.3 mg）をジメチルホルムアミド（300 μL）に懸濁し、19.2 GBqの[11C]CO2から誘導した[11C]CH3Iを室温にて吹き込んだ。次いで100℃にて3分間加熱した。反応物を放冷後、溶媒 (50 mmol/L リン酸水溶液：アセトニトリル＝4:1) を1 ml加え、HPLCを用いて精製した。HPLCカラムはSunfire C18 (250×10 mm)を用い、移動相は50 mmol/Lリン酸水溶液とアセトニトリルの体積比が4:1である溶媒を用い、流速は5 ml/minで行った。10分から12分に溶出したフラクションを25% アスコルビン酸 (100 μL)とTween 80/エタノール混合溶媒 (100 μL)を加えたなすフラスコに分取した後、減圧濃縮を行った。次いで0.5 mMリン酸ナトリウム補正液(1 ml)と注射用水(2 ml)の混合溶液にて再溶解を行い、1.91 GBqの表題化合物を含む溶液を得た。分析HPLCにて当該標識体の保持時間と非標識体の保持時間が同等であることを確認した。HPLCカラムはX-Terra C18 (150×4.6 mm)を用い、移動相は50 mmol/Lリン酸水溶液とアセトニトリルの体積比が4:1である溶媒を用い、流速は1 ml/minで行った。
(Method 1)
Precursor B (1.0 mg) and cesium carbonate (10.0 mg) obtained in Example B-1- (5) were suspended in dimethyl sulfoxide (300 μL) and derived from 35.5 GBq [ 11 C] CO 2 [ 11 C] CH 3 I was blown at room temperature. Subsequently, it heated at 100 degreeC for 3 minute (s). After allowing the reaction to cool, 1 ml of a solvent (50 mmol / L phosphoric acid aqueous solution: acetonitrile = 4: 1) was added and purified using HPLC. The HPLC column was X-Terra C18 (250 × 10 mm), the mobile phase was a solvent with a volume ratio of 50: 1 mmol / L phosphoric acid aqueous solution and acetonitrile, and the flow rate was 4 ml / min. . The fraction eluted from 11 to 12 minutes was collected in a flask containing 25% ascorbic acid (100 μL) and Tween 80 / ethanol mixed solvent (100 μL), and then concentrated under reduced pressure. Subsequently, it was redissolved with a mixed solution of 0.5 mM sodium phosphate correction solution (1 ml) and water for injection (2 ml) to obtain a solution containing 0.81 GBq of the title compound. It was confirmed by analytical HPLC that the retention time of the labeled body was the same as that of the unlabeled body. The HPLC column was X-Terra C18 (150 × 4.6 mm), the mobile phase was a solvent with a volume ratio of 50: 1 / mmol of phosphoric acid and acetonitrile, and the flow rate was 1 ml / min. .
(Method 2)
Precursor B (1.0 mg) and potassium carbonate (10.3 mg) obtained in Example B-1- (5) were suspended in dimethylformamide (300 μL) and derived from 19.2 GBq [ 11 C] CO 2 [ 11 C] CH 3 I was blown at room temperature. Subsequently, it heated at 100 degreeC for 3 minute (s). After allowing the reaction to cool, 1 ml of a solvent (50 mmol / L phosphoric acid aqueous solution: acetonitrile = 4: 1) was added and purified using HPLC. The HPLC column was Sunfire C18 (250 × 10 mm), the mobile phase was a solvent having a volume ratio of 50: 1 mmol / L phosphoric acid aqueous solution to acetonitrile, and the flow rate was 5 ml / min. The fraction eluted from 10 to 12 minutes was fractionated into a flask containing 25% ascorbic acid (100 μL) and Tween 80 / ethanol mixed solvent (100 μL), and then concentrated under reduced pressure. Subsequently, it was redissolved with a mixed solution of 0.5 mM sodium phosphate correction solution (1 ml) and water for injection (2 ml) to obtain a solution containing 1.91 GBq of the title compound. It was confirmed by analytical HPLC that the retention time of the labeled body was the same as that of the unlabeled body. The HPLC column was X-Terra C18 (150 × 4.6 mm), the mobile phase was a solvent with a volume ratio of 50: 1 / mmol of phosphoric acid and acetonitrile, and the flow rate was 1 ml / min. .
試験例１
・Ｖ１ｂ受容体結合試験
ヒトＶ１ｂ受容体を一過性に発現させた２９３ＦＴ細胞を回収し、１５ｍｍｏｌ／Ｌ トリス塩酸緩衝液（ｐＨ７．４、２ｍｍｏｌ／Ｌ 塩化マグネシウム、０．３ｍｍｏｌ／Ｌ エチレンジアミン四酢酸、１ｍｍｏｌ／Ｌ グリコールエーテルジアミン四酢酸を含む）中でホモジナイズした。得られたホモジネートを５０，０００×ｇ、４℃で２０分間遠心分離し、沈殿物を７５ｍｍｏｌ／Ｌ トリス塩酸緩衝液（ｐＨ７．４、１２．５ｍｍｏｌ／Ｌ 塩化マグネシウム、０．３ｍｍｏｌ／Ｌ エチレンジアミン四酢酸、１ｍｍｏｌ／Ｌ グリコールエーテルジアミン四酢酸、２５０ｍｍｏｌ／Ｌ ショ糖を含む）に再懸濁して粗膜標品とし、結合試験実施前まで−８０℃にて保存した。結合試験の際は、この粗膜標品を５０ｍｍｏｌ／Ｌ トリス塩酸緩衝液（ｐＨ７．４、１０ｍｍｏｌ／Ｌ 塩化マグネシウム、０．１％ ウシ血清アルブミンを含む）にて希釈し、各被検化合物、及び［3Ｈ］ＡＶＰ（最終濃度０．４〜１ｎｍｏｌ／Ｌ）と混合し、室温で６０分間インキュベーションした。被検化合物はＤＭＳＯにて段階的に希釈し、混合時の被検化合物の最終濃度は、０．０１ｎｍｏｌ／Ｌ〜１μｍｏｌ／Ｌである。インキュベーション後、混合溶液を０．３％ ポリエチレンイミンを浸透させたＧＦ／Ｃフィルターへと吸引濾過した。このＧＦ／Ｃフィルターを乾燥させてシンチレーターを加えた後、トップカウント（パーキンエルマー社）を用いてフィルター上に残存する放射能を測定した。１０μｍｏｌ／Ｌの未標識ＡＶＰ存在下での放射能を０％とし、未標識ＡＶＰ非存在下での放射能を１００％とした。各濃度の被検化合物存在下での放射能より用量反応曲線を作成し、被検化合物の５０％阻害濃度（ＩＣ50値）を算出した。化合物Ａ−１−４及びＢ−１−４のＩＣ50値を表１に示す。
Test example 1
-V1b receptor binding test 293FT cells in which human V1b receptor was transiently expressed were collected, and 15 mmol / L Tris-HCl buffer (pH 7.4, 2 mmol / L magnesium chloride, 0.3 mmol / L ethylenediaminetetraacetic acid). In 1 mmol / L glycol ether diamine tetraacetic acid). The obtained homogenate was centrifuged at 50,000 × g for 20 minutes at 4 ° C., and the precipitate was added to 75 mmol / L Tris-HCl buffer (pH 7.4, 12.5 mmol / L magnesium chloride, 0.3 mmol / L ethylenediamine tetrachloride). Acetic acid, 1 mmol / L glycol ether diamine tetraacetic acid, 250 mmol / L sucrose included) was resuspended to prepare a crude film sample, and stored at −80 ° C. until the binding test was performed. In the binding test, the crude membrane preparation was diluted with 50 mmol / L Tris-HCl buffer (pH 7.4, 10 mmol / L magnesium chloride, containing 0.1% bovine serum albumin), and each test compound, And [ 3 H] AVP (final concentration 0.4-1 nmol / L) and incubated for 60 minutes at room temperature. The test compound is diluted stepwise with DMSO, and the final concentration of the test compound at the time of mixing is 0.01 nmol / L to 1 μmol / L. After the incubation, the mixed solution was suction filtered through a GF / C filter infiltrated with 0.3% polyethyleneimine. After drying this GF / C filter and adding a scintillator, the radioactivity remaining on the filter was measured using a top count (Perkin Elmer). The radioactivity in the presence of 10 μmol / L unlabeled AVP was 0%, and the radioactivity in the absence of unlabeled AVP was 100%. A dose response curve was prepared from the radioactivity in the presence of each concentration of the test compound, and the 50% inhibitory concentration (IC 50 value) of the test compound was calculated. The IC 50 values of compounds A-1-4 and B-1-4 are shown in Table 1.
試験例２
・ＰＥＴイメージング
方法
ＰＥＴ撮像には雄性アカゲザルを用いた。サルはイソフルラン（1.5% v/v）によって持続的に麻酔し、伏在静脈に放射性標識化合物および薬液投与のための留置針を設置した。ＰＥＴ撮像は小動物用PET Focus 220 (Siemens)を使用し、イソフルラン麻酔下のサルを同機器に測定用の姿勢にて固定した。ＰＥＴ撮像中は、動物を保温マットにて覆い体温の維持を行い、パルスオキシメータで状態を管理した。
Test example 2
・ PET imaging
Method Male rhesus monkeys were used for PET imaging. The monkeys were continuously anesthetized with isoflurane (1.5% v / v) and an indwelling needle was placed in the saphenous vein for administration of the radiolabeled compound and drug solution. For PET imaging, PET Focus 220 (Siemens) for small animals was used, and a monkey under isoflurane anesthesia was fixed to the same device in a measurement posture. During PET imaging, the animal was covered with a heat insulating mat to maintain the body temperature, and the state was controlled with a pulse oximeter.
放射性標識化合物Ａ−１（388 MBq/サル個体）を静脈内投与し、投与直後から９０分間のPET撮像を行った。撮像はリストモードで実施し、0.5 mm Hanningフィルターを用いて画像再構成を行った。得られたＰＥＴイメージデータは、PMOD software (PMOD Technology)を使用し、放射性標識化合物分布の三次元マップの構築、および下垂体に設定したregion of interest（ROI）での放射能濃度の時間変化の解析に用いた。 Radiolabeled compound A-1 (388 MBq / monkey individual) was intravenously administered, and PET imaging was performed for 90 minutes immediately after administration. Imaging was performed in list mode, and image reconstruction was performed using a 0.5 mm Hanning filter. The obtained PET image data uses PMOD software (PMOD Technology) to construct a three-dimensional map of the distribution of radiolabeled compounds, and the time-dependent changes in radioactivity concentration in the region of interest (ROI) set in the pituitary gland. Used for analysis.
放射性標識化合物Ａ−１の下垂体での放射能集積の低下を確認するため、同じ個体のサルを使用し、非標識化合物Ａ−1―４を前投与（10 mg/kg、伏在静脈より投与）し、直後に放射性標識化合物Ａ−１（352 MBq/サル個体）を投与し、放射性標識化合物投与直後から９０分間のＰＥＴ撮像を行った（Blocking試験）。 In order to confirm the decrease in radioactivity accumulation in the pituitary gland of radiolabeled compound A-1, the same monkey was used and pre-administered unlabeled compound A-1-4 (10 mg / kg, from saphenous vein) The radiolabeled compound A-1 (352 MBq / monkey individual) was administered immediately, and PET imaging was performed for 90 minutes immediately after the radiolabeled compound administration (Blocking test).
放射性標識化合物Ｂ−１（341 MBq/サル個体）を静脈内投与し、投与直後から90分までの間のPET撮像を行った。また、下垂体での放射能集積の低下は、非標識化合物Ｂ−１―４を前投与（10 mg/kg、伏在静脈より投与）し、直後に放射性標識化合物Ｂ−１（303 MBq/サル個体）を投与し、放射性標識化合物投与直後から90分間のPET撮像を行った。PET撮像、画像再構成およびＰＥＴイメージデータの解析は、放射性標識化合物Ａ−１と同様の方法を用いた。 Radiolabeled compound B-1 (341 MBq / monkey individual) was intravenously administered, and PET imaging was performed for 90 minutes immediately after administration. In addition, the decrease in radioactivity accumulation in the pituitary gland was caused by pre-administration of unlabeled compound B-1-4 (10 mg / kg, administered from the saphenous vein), and immediately after that radiolabeled compound B-1 (303 MBq / Monkeys) and PET imaging was performed for 90 minutes immediately after administration of the radiolabeled compound. PET imaging, image reconstruction, and analysis of PET image data used the same methods as for radiolabeled compound A-1.
試験結果
試験結果を図１及び２に示す。
Test results The test results are shown in FIGS.
図１に示されている通り、放射性標識化合物Ａ−１を使用した試験において、放射性標識化合物Ａ−１の投与直後より、V1b受容体の高い発現を認める下垂体において放射能濃度の上昇を確認した。下垂体への放射能の取り込みは投与2分後にピークに達し、そのピークの取り込み量は0.11％Injected dose (ID)/mLであった。ピークに達した後は徐々にその放射能は低下し、投与90分後での取り込み量は0.044％ID/mLであった。下垂体以外の頭部内の組織において、下垂体と同様の放射能の取り込みは認められなかった。 As shown in FIG. 1, in a test using radiolabeled compound A-1, an increase in radioactivity concentration was confirmed in the pituitary gland where high expression of V1b receptor was observed immediately after administration of radiolabeled compound A-1. did. The uptake of radioactivity into the pituitary reached a peak 2 minutes after administration, and the peak uptake was 0.11% Injected dose (ID) / mL. The radioactivity gradually decreased after reaching the peak, and the uptake at 90 minutes after administration was 0.044% ID / mL. The uptake of radioactivity similar to that of the pituitary gland was not observed in tissues in the head other than the pituitary gland.
非標識化合物Ａ−１を前投与することにより、下垂体での放射能取り込みは、投与1分後でピークに達し、そのピーク値の取り込み量は0.085％ID/mLであった。ピークに達した後、放射能は低下し、投与90分後での取り込み量は0.012％ID/mLであった。放射性標識化合物Ａ−１単独投与での試験結果と比較し、下垂体での放射能の取り込みは低下した。 By pre-administering unlabeled compound A-1, radioactivity uptake in the pituitary gland reached a peak 1 minute after administration, and the peak value uptake was 0.085% ID / mL. After reaching the peak, the radioactivity decreased, and the uptake at 90 minutes after administration was 0.012% ID / mL. The radioactivity uptake in the pituitary gland was reduced as compared with the test results obtained with the radiolabeled compound A-1 alone.
図２に示されている通り、放射性標識化合物Ｂ−１を使用した試験において、放射性標識化合物Ｂ−１の投与直後より下垂体において放射能濃度の上昇を確認した。下垂体への放射能の取り込みは投与2分後にピークに達し、そのピークの取り込み量は0.13％Injected dose (ID)/mLであった。ピークに達した後は徐々にその放射能は低下し、投与90分後での取り込み量は0.068％ID/mLであった。下垂体以外の頭部内の組織において、下垂体と同様の放射能の取り込みは認められなかった。 As shown in FIG. 2, in the test using radiolabeled compound B-1, an increase in radioactivity concentration was confirmed in the pituitary gland immediately after administration of radiolabeled compound B-1. The uptake of radioactivity into the pituitary reached a peak 2 minutes after administration, and the peak uptake was 0.13% Injected dose (ID) / mL. The radioactivity gradually decreased after reaching the peak, and the uptake at 90 minutes after administration was 0.068% ID / mL. The uptake of radioactivity similar to that of the pituitary gland was not observed in tissues in the head other than the pituitary gland.
非標識化合物Ｂ−１−４を前投与することにより、下垂体での放射能取り込みは、投与2分後でピークに達し、そのピーク値の取り込み量は0.078％ID/mLであった。ピークに達した後、放射能は低下し、投与90分後での取り込み量は0.008％ID/mLであった。放射性標識化合物Ｂ−１単独投与での試験結果と比較し、下垂体での放射能の取り込みは低下した。 By pre-administering unlabeled compound B-1-4, the radioactivity uptake in the pituitary gland reached a peak 2 minutes after administration, and the uptake of the peak value was 0.078% ID / mL. After reaching the peak, the radioactivity decreased and the uptake 90 minutes after administration was 0.008% ID / mL. The radioactivity uptake in the pituitary gland was reduced as compared with the test results with the radiolabeled compound B-1 alone.
同じ個体のサル脳の核磁気共鳴画像と重ね合わせた放射性標識化合物Ａ−１投与30から90分の間のPET加算画像を図１に示す。(a) 放射性標識化合物Ａ−１のみ投与したサル（冠状断面図）、(ｂ) 放射性標識化合物Ａ−１のみ投与したサル（矢状断面図）、(ｃ) 非標識化合物Ａ−１−４を前投与後、放射性標識化合物Ａ−１を投与したサル（冠状断面図）、(ｄ) 非標識化合物Ａ−１−４を前投与後、放射性標識化合物Ａ−１を投与したサル（矢状断面図）。同じ個体のサル脳の核磁気共鳴画像と重ね合わせた放射性標識化合物Ｂ−１投与30から90分の間のPET加算画像を図2に示す。(a) 放射性標識化合物Ｂ−１のみ投与したサル（冠状断面図）、(ｂ) 放射性標識化合物Ｂ−１のみ投与したサル（矢状断面図）、(ｃ) 非標識化合物Ｂ−１−４を前投与後、放射性標識化合物Ｂ−１を投与したサル（冠状断面図）、(ｄ) 非標識化合物Ｂ−１−４を前投与後、放射性標識化合物Ｂ−１を投与したサル（矢状断面図）。各図中の右上埋め込み図は矢印部分（下垂体に相当）の拡大図。 FIG. 1 shows a PET addition image for 30 to 90 minutes after administration of the radiolabeled compound A-1 superimposed on the nuclear magnetic resonance image of the monkey brain of the same individual. (a) monkey administered only with radiolabeled compound A-1 (coronary cross section), (b) monkey administered with only radiolabeled compound A-1 (sagittal cross section), (c) unlabeled compound A-1-4 After administration of radiolabeled compound A-1 (coronary sectional view), (d) monkey (sagittal) administered with radiolabeled compound A-1 after preadministration of unlabeled compound A-1-4 Sectional view). FIG. 2 shows a PET addition image for 30 to 90 minutes after administration of the radiolabeled compound B-1 superimposed on the nuclear magnetic resonance image of the monkey brain of the same individual. (a) monkey administered with radiolabeled compound B-1 only (coronal cross section), (b) monkey administered with radiolabeled compound B-1 only (sagittal cross section), (c) unlabeled compound B-1-4 Monkey (coronary cross-sectional view) administered with radiolabeled compound B-1 after pre-administration, (d) monkey (sagittal) administered with radiolabeled compound B-1 after pre-administration of non-labeled compound B-1-4 Sectional view). The upper right embedded diagram in each figure is an enlarged view of an arrow portion (corresponding to a pituitary gland).
本発明は、ＰＥＴ等の画像診断技術を用いてバソプレッシンＶ１ｂ受容体の機能変化に起因する各種疾患の診断をするために有用である。また、バソプレッシンＶ１ｂ受容体拮抗物質又は作動物質を各種病気の治療薬として使用するに当たって、ＰＥＴ等の画像診断技術を用いてその有効量を推定するためにも有用である。 The present invention is useful for diagnosing various diseases caused by functional changes of the vasopressin V1b receptor using diagnostic imaging techniques such as PET. In addition, when a vasopressin V1b receptor antagonist or agonist is used as a therapeutic agent for various diseases, it is also useful for estimating the effective amount using an image diagnostic technique such as PET.
Claims (10)
Ｘは、ＣＨ又はＮを示し、
Ｒ1は、Ｃ1-5アルキル（該Ｃ1-5アルキルはヒドロキシ、ハロゲン原子、シアノ、Ｃ3-7シクロアルキル、及びＣ1-5アルコキシからなる群より選ばれる同一又は異なった１〜３個の置換基で置換されても良い）であり、
Ｒ2は、同一又は異なった１〜３個のハロゲン原子で置換されても良いＣ1-5アルキル基であり、
ここで、Ｒ2は、11Ｃ、18Ｆ、123Ｉ、125Ｉ、131Ｉ、75Ｂｒ、76Ｂｒ及び82Ｂｒからなる群より選ばれる１つの放射性同位元素で標識されている。］ A compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof.
X represents CH or N;
R 1 is C 1-5 alkyl (the C 1-5 alkyl is the same or different 1-3 selected from the group consisting of hydroxy, halogen atom, cyano, C 3-7 cycloalkyl, and C 1-5 alkoxy. May be substituted with one substituent),
R 2 is a C 1-5 alkyl group which may be substituted with 1 to 3 halogen atoms which are the same or different,
Here, R 2 is labeled with one radioisotope selected from the group consisting of 11 C, 18 F, 123 I, 125 I, 131 I, 75 Br, 76 Br, and 82 Br. ]
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013264135A JP6376376B2 (en) | 2013-12-20 | 2013-12-20 | Radiolabeled ligand of V1b receptor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013264135A JP6376376B2 (en) | 2013-12-20 | 2013-12-20 | Radiolabeled ligand of V1b receptor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015120644A true JP2015120644A (en) | 2015-07-02 |
| JP6376376B2 JP6376376B2 (en) | 2018-08-22 |
Family
ID=53532649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013264135A Active JP6376376B2 (en) | 2013-12-20 | 2013-12-20 | Radiolabeled ligand of V1b receptor |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6376376B2 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009017236A1 (en) * | 2007-08-01 | 2009-02-05 | Taisho Pharmaceutical Co., Ltd. | Pyridopyrimidin-4-one derivatives |
| JP2010173974A (en) * | 2009-01-30 | 2010-08-12 | Taisho Pharmaceutical Co Ltd | New use of medicine containing pyridopyrimidine-4-one derivative |
| JP2010173978A (en) * | 2009-01-30 | 2010-08-12 | Taisho Pharmaceutical Co Ltd | Pyridopyrimidin-4-one derivative |
-
2013
- 2013-12-20 JP JP2013264135A patent/JP6376376B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009017236A1 (en) * | 2007-08-01 | 2009-02-05 | Taisho Pharmaceutical Co., Ltd. | Pyridopyrimidin-4-one derivatives |
| JP2010173974A (en) * | 2009-01-30 | 2010-08-12 | Taisho Pharmaceutical Co Ltd | New use of medicine containing pyridopyrimidine-4-one derivative |
| JP2010173978A (en) * | 2009-01-30 | 2010-08-12 | Taisho Pharmaceutical Co Ltd | Pyridopyrimidin-4-one derivative |
Non-Patent Citations (3)
| Title |
|---|
| BIOORG. MED. CHEM., vol. 14, JPN6017028978, 2006, pages 8599 - 8607, ISSN: 0003723396 * |
| EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 46, JPN6017028980, 2011, pages 4760 - 4767, ISSN: 0003723397 * |
| J. MED. CHEM., vol. 51, JPN6017028981, 2008, pages 5833 - 5842, ISSN: 0003723398 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP6376376B2 (en) | 2018-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Luo et al. | Syntheses and in vitro evaluation of new S1PR1 compounds and initial evaluation of a lead F-18 radiotracer in rodents | |
| TWI568714B (en) | Compositions, methods, and systems for the synthesis and use of imaging agents | |
| TW201702217A (en) | Compositions, methods and systems for the synthesis and use of imaging agents | |
| US9987381B2 (en) | Radioligands for imaging the LPA-1 receptor | |
| JP2022508699A (en) | Radioligand for imaging LPA1 receptor | |
| Mu et al. | Synthesis and pharmacological evaluation of [11C] granisetron and [18F] fluoropalonosetron as PET probes for 5-HT3 receptor imaging | |
| TW200820988A (en) | Radiofluorination | |
| JP4554202B2 (en) | Radiolabeled neuropeptide YY5 receptor antagonist | |
| JP6376376B2 (en) | Radiolabeled ligand of V1b receptor | |
| JP5441060B2 (en) | Kit for producing a molecular probe for PET screening for drug discovery | |
| US20170174632A1 (en) | 4-oxo-1, 4-dihydroquinoline-3-carboxamide as selective ligand for cannabinoid receptor 2 for diagnosis and therapy | |
| JP5744057B2 (en) | Aryloxyanilide imaging agent | |
| JP6218366B2 (en) | Radiolabeled ligand for H3 receptor | |
| JP2012509887A (en) | Imaging ligand | |
| KR101519006B1 (en) | Novel benzamide derivative or pharmaceutically acceptable salt thereof, preparation method thereof and pharmaceutical composition for diagnosis of cancer disease containing the same as an active ingredient | |
| JP2014521628A (en) | New compounds | |
| JP6273251B2 (en) | Aromatic amino acid derivative and PET probe using the same | |
| JP6488045B2 (en) | Compounds suitable for detection of acetylcholine vesicle transporters | |
| JP6187460B2 (en) | Pyridopyrimidin-4-one derivatives | |
| NL2013049B1 (en) | 6,7-Dioxyalkyltetrahydroisoquinoline Compounds. | |
| WO2023278729A1 (en) | Chromane imaging ligands | |
| JP2016513083A (en) | Radiolabeled compound | |
| JP6496101B2 (en) | Compounds suitable for detection of acetylcholine vesicle transporters | |
| EP1545525A2 (en) | Radiolabeled neurokinin-1 receptor antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20161118 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20161118 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170803 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170803 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170927 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20170927 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20180122 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20180329 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20180329 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180420 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20180608 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180628 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180711 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6376376 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |